On July 29, 2022 AstraZeneca reported its first half 2022 financial results (Press release, AstraZeneca, JUL 29, 2022, View Source [SID1234618749]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
H1 2022 Financial performance (growth numbers and commentary at CER)
‒ Total Revenue increased 48% to $22,161m, with growth coming from all disease areas and from the addition
of Alexion
‒ Total Revenue from Oncology increased 22%5
, including receipt of a milestone payment. Product Sales from
Oncology increased 18%. Total Revenue from R&I6
increased 3%, CVRM7
increased 19%8 and Rare
Disease increased 10%8
. Excluding a one-off historical pricing adjustment, Rare Disease increased 8%
‒ Core Gross Margin of 81%, with the second quarter benefitting from currency fluctuations, and phasing of
COVID-19 medicine contracts
‒ Core Operating Margin of 33%. Core Total Operating Expense increased 33%, reflecting the addition of
Alexion, and continued investment in new launches and the pipeline to build industry-leading mid-to-long
term growth
‒ Core EPS of $3.61, with the second quarter benefitting from a Core Tax Rate of 15%. The FY 2022
expectation for the Core Tax Rate remains 18-22%
‒ Interim dividend declared of $0.93 (76.4 pence, 9.49 SEK) per ordinary share, reflecting the Board’s intent
to increase to $2.90 in FY 2022, as announced at FY 2021
‒ FY 2022 Total Revenue guidance at CER increased due to an updated outlook for COVID-19 medicines and
continued strong performance of the overall business, enabling further investment in the pipeline. With an
expectation that Other Operating Income in H2 2022 will be similar to H1 2022, EPS guidance is unchanged
Key milestones achieved since the prior results
‒ Key data: Positive read-outs for Farxiga in HFpEF9
(DELIVER), Imfinzi in early NSCLC10 (AEGEAN),
eplontersen in ATTRv-PN11 (NEURO-TTRansform) and Ultomiris in NMOSD12 (CHAMPION-NMOSD). Full
results from the Enhertu DESTINY-Breast04 trial in HER213
-low breast cancer, presented at ASCO (Free ASCO Whitepaper)
‒ Key approvals: Enhertu for HER2-positive breast cancer (DESTINY-Breast03) in the US and EU; positive
CHMP14 opinions in the EU for Tezspire in severe asthma (NAVIGATOR), Lynparza15 in early breast cancer
(OlympiA) and Ultomiris in gMG16 (CHAMPION-MG)
‒ Other regulatory milestones: US Priority Review for Imfinzi in biliary tract cancer (TOPAZ-1) and Enhertu in
HER2-low metastatic breast cancer (DESTINY-Breast04), China Priority Review for Koselugo in NF1-PN17
Pascal Soriot, Chief Executive Officer, AstraZeneca, said:
"AstraZeneca had a strong financial first half of 2022, and great pipeline delivery. We announced practicechanging data for several medicines including Enhertu in breast cancer, Farxiga in heart failure and Ultomiris in
neuromyelitis optica spectrum disorder.
2
We have made great progress in our efforts to combat COVID-19. Vaxzevria is estimated to have saved more
than six million lives during the first year of roll-out, and Evusheld has protected hundreds of thousands of
immunocompromised people, enabling them to return to a more normal life. Evusheld continues to demonstrate
activity against new variants.
Given the ongoing performance of our underlying business and the contribution of our COVID-19 medicines,
we are updating our revenue guidance for 2022. This has enabled us to increase our R&D investment in the
exciting number of pipeline opportunities that can benefit patients and drive long term sustainable growth for
our company. We look forward to announcing the results of several important late-stage trials this year and next".
Guidance
The Company updates FY 2022 guidance due to strength in its overall business, an updated outlook for
COVID-19 medicines, as well as increased investment in R&D to drive long term sustainable growth.
Total Revenue is expected to increase by a low twenties percentage (previously high teens)
Core EPS is expected to increase by a mid-to-high twenties percentage (unchanged)
‒ The CER growth rates include the full-year contribution of Vaxzevria in both FY 2021 and FY 2022
‒ Total Revenue from COVID-19 medicines is anticipated to be broadly flat versus FY 2021 (previously a lowto-mid twenties percentage decline), with growth in Evusheld offsetting an expected decline in Vaxzevria
sales. The majority of Vaxzevria revenue in 2022 is expected to come from initial contracts
‒ As previously indicated, the Gross Margin from the COVID-19 medicines is expected to be lower than the
Company average
‒ Core Operating Expenses are expected to increase by a mid-to-high teens percentage, driven in part by the
full year integration of Alexion expenses. (Previous guidance was a low-to-mid teens percentage increase.
The update is a result of increased R&D spend following positive trial readouts, and increased spend to
support new launches, including Evusheld)
‒ Other Operating Income in H2 2022 is expected to be similar to the level seen in H1 2022
‒ Emerging Markets Total Revenue, including China, is expected to grow by a mid single-digit percentage in
FY 2022 (unchanged). China Total Revenue is expected to decline by a mid single-digit percentage in FY
2022 (unchanged), primarily due to the continued NRDL18 and VBP19 programmes impacting various
medicines. The Company remains confident in the longer-term outlook for Emerging Markets, driven by a
large market opportunity, broader patient access and an increased mix of new medicines
‒ A Core Tax Rate between 18-22% (unchanged)
AstraZeneca continues to recognise and actively manage the heightened risks from COVID-19 and geopolitical
and supply chain uncertainties on overall business performance. Variations in performance between quarters
can be expected to continue.
The Company is unable to provide guidance on a Reported basis because AstraZeneca cannot reliably forecast
material elements of the Reported result, including any fair value adjustments arising on acquisition-related
liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the cautionary
statements section regarding forward-looking statements at the end of this announcement.
Currency impact
If foreign-exchange rates for July to December 2022 were to remain at the spot rates seen on 30 June 2022, it
is anticipated that FY 2022 Total Revenue would incur a mid single-digit adverse impact (previously a low singledigit adverse impact) versus the financials at CER, and, as previously indicated, FY 2022 Core EPS would incur
a mid-single-digit adverse impact.
The Company’s foreign-exchange rate sensitivity analysis is contained in Table 18.
3
Table 1: Key elements of Total Revenue performance in Q2 2022
% Change
Revenue type $m Actual CER
Product Sales 10,630 32 38 $1,776m from medicines acquired with Alexion
Collaboration Revenue 141 (20) (20) $100m for Enhertu (Q2 2021: $46m)
$13m for Tezspire (Q2 2021: $nil)
Total Revenue 10,771 31 37
Disease areas $m Actual CER
Oncology 3,810 15 20 Good performance across key medicines and
regions, despite lower diagnosis rates and
adverse impact in China from COVID-19-related
lockdowns
CVRM8 2,356 14 19 Farxiga achieved another blockbuster quarter with
$1,104m in revenues in the quarter
R&I 1,395 (2) 1 Growth across Breztri and Fasenra offsetting a
decline in Pulmicort of 30% (28% at CER)
primarily due to the impact of VBP
implementation and COVID-19 lockdowns in
China
V&I20 981 7 12 $455m from Vaxzevria21
, $445m from Evusheld
Majority of Vaxzevria revenue from initial
contracts
Rare Disease8 1,801 6 12 Durable C5 franchise growth, including continued
conversion to Ultomiris in PNH and aHUS and
launch in gMG in the US
Excluding a one-off historic pricing adjustment in
Q2 that benefitted ex-US Total Revenue, Rare
Disease pro forma revenue growth would have
been 2% (8% at CER)
Other Medicines 427 (17) (10)
Total Revenue 10,771 31 37
Regions inc. Vaxzevria $m Actual CER
Emerging Markets 2,792 (3) 1
– China 1,435 (6) (5) Pricing pressure associated with the NRDL and
VBP programmes
COVID-19-related lockdowns
– Ex-China Emerging Markets 1,357 1 7
US 4,348 72 72
Europe 2,080 21 35
Established RoW 1,550 39 55
Total Revenue inc. Vaxzevria 10,771 31 37
Regions exc. Vaxzevria $m Actual CER Contribution of medicines acquired with Alexion
Emerging Markets 2,603 7 11 $81m
– China 1,435 (6) (5)
– Ex-China Emerging Markets 1,167 31 39 $81m
US 4,348 72 72 $1,041m
Europe 1,952 43 59 $377m
Established RoW 1,412 39 56 $277m
Total Revenue exc. Vaxzevria 10,316 41 47 $1,776m
4
Table 2: Key elements of financial performance in Q2 2022
Metric
($m or %)
Reported Reported
change
Core Core
change
Comments22
Total
Revenue $10,771m 31% Actual
37% CER $10,771m 31% Actual
37% CER
See Table 1 and the Total Revenue section of
this document for further details
Gross
Margin23 72% (1pp) Actual
(2pp) CER 83% 10% Actual
8% CER
+ Addition of Alexion
+ Increasing mix of Oncology sales
+ Positive effect from phasing of COVID-19
contracts
+ Positive impact from currency fluctuations
‒ China impact of NRDL and VBP
‒ Impact from profit-sharing arrangements (e.g.
Lynparza)
‒ Reported Gross Margin impacted by unwind
of Alexion inventory fair value adjustment
Foreign exchange fluctuations may have a
positive or negative impact on Gross Margin
in future quarters
R&D
Expense $2,546m 39% Actual
44% CER $2,431m 35% Actual
40% CER
+ Addition of Alexion
+ Increased investment in the pipeline following
un-gating of additional late-stage trials
+ One-off $89m impairment (included in
Reported and Core) of a pre-paid asset
relating to a discontinued collaboration with
an external partner
+ Reversal of the beneficial cost phasing effects
seen in Q1 2022
Core R&D-to-Total Revenue ratio of 23% (Q2
2021: 22%)
SG&A
Expense $4,681m
51% Actual
56% CER $3,137m 27% Actual
33% CER
+ Addition of Alexion
+ Market development activities for recent
launches, including Evusheld
+ Core SG&A-to-Total Revenue ratio of 29%
(Q2 2021: 30%)
Other
Operating
Income24
$122m (5%) Actual
(5%) CER $112m
(12%) Actual
(13%) CER
Includes $61m divestment from Plendil, and
income coming from royalties and prior
transactions
Operating
Margin 5% (9pp) Actual
(9pp) CER 31% 9% Actual
8% CER
See Gross Margin and Expenses
commentary above
Net Finance
Expense $293m (8%) Actual
10% CER $223m
1% Actual
26% CER
+ Alexion debt financing costs
‒ Reported impacted by lower discount unwind
on acquisition-related liabilities
Tax Rate (46%) n/m 15% (8%) Actual
(9%) CER
15% tax rate in the quarter reflected
geographical mix of profits and favourable
adjustments to prior year tax liabilities in a
number of major jurisdictions
Variations in the tax rate can be expected to
continue quarter to quarter
Full year expectation remains 18-22%
EPS $0.23 (45%) Actual
(46%) CER $1.72 92% Actual
89% CER
Further details of differences between
Reported and Core are shown in Table 13
5
Corporate and business development
In May 2022, AstraZeneca entered into a licence agreement with RQ Biotechnologies Ltd for a portfolio of earlystage mAbs25 targeted against SARS-CoV-2, the virus that causes COVID-19. Under the agreement,
AstraZeneca acquired an exclusive worldwide licence to develop, manufacture and commercialise mAbs
against SARS-CoV-2.
Also in May, AstraZeneca completed the sale of commercial rights to Plendil in 35 markets globally, resulting in
a $61m gain being recognised in Other Operating Income in the quarter.
In June 2022, the Company entered into a broad strategic collaboration with GRAIL, LLC to develop and
commercialise companion diagnostic assays for use with AstraZeneca’s therapies. The collaboration will initially
focus on developing companion diagnostic tests to identify patients with high-risk, early-stage disease, with
plans to embark on numerous trials across multiple indications over the next several years. The deal also
encompasses the use of GRAIL’s technology to enable recruitment of patients with early-stage cancer for
AstraZeneca’s clinical trials.
In July 2022, AstraZeneca announced an agreement to acquire TeneoTwo, Inc., including its Phase I clinicalstage CD19xCD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell nonHodgkin lymphoma. AstraZeneca will acquire all outstanding equity of TeneoTwo in exchange for an upfront
payment of $100m on deal closing. Under the terms of the agreement, AstraZeneca will make additional
contingent R&D-related milestone payments of up to $805m and additional contingent commercial-related
milestone payments of up to $360m to TeneoTwo’s equity holders. The transaction is expected to close in the
third quarter of 2022.
Sustainability summary
Airfinity, an independent provider of global real-time health intelligence, estimates that the AstraZeneca COVID19 vaccine saved over six million lives during the period 8 December 2020 to 8 December 2021. This analysis
is based on data from Imperial College, London, published in The Lancet in June 2022.
Management changes
AstraZeneca PLC reported the appointment of Michel Demaré as the Chair-designate of the Board.
His appointment followed a robust succession planning process led by Philip Broadley in his capacity as senior
independent Non-Executive Director.
As previously communicated, Leif Johansson, current Chair of the Board of AstraZeneca will be retiring at the
conclusion of the Company’s Annual General Meeting in April 2023. Michel’s appointment is effective
immediately thereafter allowing for a managed handover period over the coming months.
Michel was appointed to the Board of AstraZeneca in September 2019 as an independent Non-Executive
Director and is currently Chair of the Company’s Remuneration Committee and member of the Audit Committee
and the Nomination and Governance Committee. He is a Non-Executive Director of Vodafone Group Plc and
Louis Dreyfus Int’l Holdings BV. He is also Chairman of IMD Business School and Chairman of Nomoko AG.
Conference call
A conference call and webcast for investors and analysts will begin today, 29 July 2022, at 11:45 BST. Details
can be accessed via astrazeneca.com.
Reporting calendar
The Company intends to publish its year-to-date and third quarter results on Thursday 10 November 2022.
6
Notes
1 Constant exchange rates. The differences between Actual Change and CER Change are due to foreign exchange
movements between periods in 2022 vs 2021. CER financial measures are not accounted for according to generally
accepted accounting principles (GAAP) because they remove the effects of currency movements from Reported
results.
2 Reported financial measures are the financial results presented in accordance with UK-adopted International
Accounting Standards and International Financial Reporting Standards (IFRSs) as issued by the International
Accounting Standards Board (IASB) and International Accounting Standards as adopted by the European Union.
3 Earnings per share.
4 Core financial measures are adjusted to exclude certain items. The differences between Reported and Core
measures are primarily due to items related to the acquisition of Alexion, amortisation of intangibles, impairments,
restructuring charges, and, as previously disclosed, a charge to provisions relating to a legal settlement with Chugai
Pharmaceutical Co. Ltd (Chugai) that led to a payment of $775m in Q2 2022. A full reconciliation between Reported
EPS and Core EPS is provided in Tables 12 and 13 in the Financial performance section of this document.
5
In FY 2022, Total Revenue from Koselugo is included in Rare Disease (FY 2021: Oncology) and Total Revenue
from Andexxa is included in BioPharmaceuticals: CVRM (FY 2021: Rare Disease). The growth rate shown for each
disease area has been calculated as though these changes had been implemented in FY 2021.
6 Respiratory & Immunology.
7 Cardiovascular, Renal and Metabolism.
8 H1 2022 and Q2 2022 growth rates on medicines acquired with Alexion have been calculated on a pro forma basis
comparing to the corresponding period in the prior year, pre-acquisition as previously published by Alexion. The
growth rates shown for the Rare Disease and CVRM disease areas include these pro forma adjustments.
9 Heart failure with preserved ejection fraction.
10 Non-small cell lung cancer.
11 Hereditary transthyretin-mediated amyloid polyneuropathy.
12 Neuromyelitis optica spectrum disorder.
13 Human epidermal growth factor receptor 2.
14 Committee for Medicinal Products for Human Use.
15 AstraZeneca is collaborating with MSD (Merck & Co., Inc. in the US and Canada) to develop and commercialise
Lynparza.
16 Generalised myasthenia gravis.
17 Neurofibromatosis type 1 plexiform neurofibromas.
18 National reimbursement drug list.
19 Volume-based procurement.
20 Vaccines & Immune Therapies.
21 Vaxzevria is AstraZeneca’s trademark for the Company’s supply of the AstraZeneca COVID-19 Vaccine. In the
financial tables in this report, ‘Vaxzevria Total Revenue’ includes Collaboration Revenue from sub-licensees that
produce and supply the AstraZeneca COVID-19 Vaccine under their own trademarks.
22 In Table 2, the ‘+ / -’ symbols indicate the directional impact of the item being discussed, e.g. a ‘+’ symbol next to
an item relating to R&D Expenses signifies that the item increased the R&D Expense relative to the prior year.
23 Gross Profit is defined as Total Revenue minus Cost of Sales. The calculation of Reported and Core Gross Margin
excludes the impact of Collaboration Revenue and any associated costs, thereby reflecting the underlying
performance of Product Sales.
24 Where AstraZeneca does not retain a significant ongoing interest in medicines or potential new medicines, income
from divestments is reported within Reported and Core Other Operating Income and Expense in the Company’s
financial statements.
25 Monoclonal antibodies.
7
Table 3: Pipeline highlights since prior results announcement
Event Medicine Indication / Trial Event
Enhertu HER2-positive breast cancer (2nd-line)
(DESTINY-Breast03)
Regulatory approval (US, EU)
Regulatory
approvals and
other regulatory
actions
Lynparza gBRCAm26 breast cancer (adjuvant)
(OlympiA) CHMP positive opinion (EU)
Tezspire Severe asthma (NAVIGATOR) CHMP positive opinion (EU)
Ultomiris gMG (CHAMPION-MG) CHMP positive opinion (EU)
Ultomiris Subcutaneous, PNH27 and aHUS28 Regulatory approval (US)
Imfinzi Biliary tract cancer (TOPAZ-1) Priority Review (US), regulatory
submission (EU)
Enhertu HER2-low breast cancer (3rd-line)
(DESTINY-Breast04)
Priority Review (US), regulatory
submission (EU, JP)
Enhertu HER2-positive breast cancer (2nd-line)
(DESTINY-Breast03) Regulatory submission (CN)
Regulatory
submissions
or acceptances
PT027 Asthma (MANDALA/DENALI) Regulatory submission (US)
Evusheld COVID-19 (PROVENT/TACKLE) Regulatory submission (JP)
Soliris gMG Regulatory submission (CN)
Koselugo NF1-PN (SPRINT) Priority Review (CN)
Imfinzi NSCLC (neoadjuvant) (AEGEAN) Primary co-endpoint met (pCR)
Major Phase III
data readouts
and other
developments
camizestrant HR+29/HER2-neg breast cancer
(SERENA-6) Fast Track Designation (US)
Farxiga HFpEF (DELIVER) Primary endpoint met
eplontersen ATTRv-PN (NEURO-TTRansform) Primary co-endpoints met
Ultomiris NMOSD (CHAMPION-NMOSD) Primary endpoint met
26 Germline (hereditary) breast cancer gene mutation.
27 Paroxysmal nocturnal haemoglobinuria.
28 Atypical haemolytic uraemic syndrome.
29 Hormone receptor positive.
8
Table 4: Pipeline – anticipated major news flow
Timing Medicine Indication / Trial Event
H2 2022 Tagrisso NSCLC (adjuvant) (ADAURA) Regulatory decision (JP)
Imfinzi Liver cancer (locoregional)
(EMERALD-1) Data readout
Imfinzi NSCLC (unresectable, Stg. III) (PACIFIC-2) Data readout
Imfinzi NSCLC (1st-line) (PEARL) Data readout
Imfinzi Biliary tract cancer (TOPAZ-1) Regulatory decision
Imfinzi +/-
tremelimumab
Liver cancer (1st-line) (HIMALAYA) Regulatory decision
Imfinzi +/-
tremelimumab
NSCLC (1st-line) (POSEIDON) Regulatory decision
Lynparza gBRCAm breast cancer (adjuvant)
(OlympiA) Regulatory decision (JP)
Lynparza Prostate cancer (1st-line) (PROpel) Regulatory submission (US), regulatory
decision
Enhertu HER2-positive breast cancer (3rd-line)
(DESTINY-Breast02)
Data readout, regulatory submission
Enhertu HER2-positive breast cancer (2nd-line)
(DESTINY-Breast03) Regulatory decision
Enhertu HER2-low breast cancer (3rd-line)
(DESTINY-Breast04)
Regulatory decision, regulatory
submission (CN)
Enhertu HER2-positive gastric cancer (2nd-line)
(DESTINY-Gastric01)
Regulatory decision (EU)
Enhertu HER2m NCSLC (2nd-line+) (DESTINYLung01)
Regulatory decision
Calquence CLL33 (ELEVATE-TN) Regulatory decision (JP)
capivasertib HR+/HER2-neg breast cancer (1st-line)
(CAPItello-291) Data readout
Farxiga HFpEF (DELIVER) Regulatory submission
Forxiga CKD34 (DAPA-CKD) Regulatory decision (CN)
eplontersen ATTRv-PN (NEURO-TTRansform) Regulatory submission (US)
Fasenra EOE35 (MESSINA) Data readout
Tezspire Severe asthma (NAVIGATOR) Regulatory decision
PT027 Asthma (MANDALA/DENALI) Regulatory decision (US)
nirsevimab RSV36 (MELODY/MEDLEY) Regulatory submission (US), regulatory
decision (EU)
Evusheld COVID-19 (PROVENT/TACKLE) Regulatory submission (CN)
Evusheld COVID-19 outpatient treatment
(TACKLE) Regulatory decision
Vaxzevria COVID-19 Regulatory submission (US)
Soliris Guillain-Barré syndrome Data readout
Ultomiris gMG (CHAMPION-MG) Regulatory decision
Ultomiris Subcutaneous, PNH and aHUS Regulatory decision (EU)
Ultomiris NMOSD (CHAMPION-NMOSD) Regulatory submission
Koselugo NF1-PN (SPRINT) Regulatory decision (JP)
H1 2023 Tagrisso EGFRm37 NSCLC (1st-line) (FLAURA2) Data readout
Tagrisso EGFRm NSCLC (unresectable Stg. III)
(LAURA) Data readout
33 Chronic lymphocytic leukaemia.
34 Chronic kidney disease.
35 Eosinophilic oesophagitis.
36 Respiratory syncytial virus.
37 Epidermal growth factor receptor mutation.
9
Imfinzi Bladder cancer (muscle invasive)
(NIAGARA)
Data readout
Imfinzi Bladder cancer (1st-line) (NILE) Data readout
Imfinzi NSCLC (neoadjuvant) (AEGEAN) Data readout
Imfinzi NSCLC (unresectable, Stg. III) (PACIFIC-2) Regulatory submission
Imfinzi Liver cancer (locoregional)
(EMERALD-1)
Regulatory submission
Imfinzi Liver cancer (adjuvant) (EMERALD-2) Data readout, regulatory submission
Imfinzi NSCLC (1st-line) (PEARL) Regulatory submission
Imfinzi SCLC (limited-stage) (ADRIATIC) Data readout
Lynparza gBRCAm38 breast cancer (adjuvant)
(OlympiA) Regulatory submission (CN)
Lynparza Ovarian cancer (1st-line) (PAOLA-1) Regulatory decision (CN)
Lynparza +
Imfinzi Ovarian cancer (1st-line) (DUO-O) Data readout
Enhertu HER2-low breast cancer (2nd-line)
(DESTINY-Breast06) Data readout
capivasertib HR+/HER2-negative breast cancer (1stline) (CAPItello-291) Regulatory submission
Dato-DXd NSCLC (3rd-line) (TROPION-Lung01) Data readout, regulatory submission
roxadustat Anaemia of myelodysplastic syndrome Data readout
Fasenra EOE (MESSINA) Regulatory submission
nirsevimab RSV (MELODY/MEDLEY) Regulatory submission (JP, CN)
danicopan PNH with extravascular haemolysis Data readout
H2 2023 Tagrisso EGFRm NSCLC (1st-line) (FLAURA2) Regulatory submission
Tagrisso EGFRm NSCLC (unresectable Stg. III)
(LAURA)
Regulatory submission
Imfinzi Biliary tract cancer (TOPAZ-1) Regulatory submission (CN)
Imfinzi Bladder cancer (muscle invasive)
(NIAGARA) Regulatory submission
Imfinzi Bladder cancer (1st-line) (NILE) Regulatory submission
Imfinzi Liver cancer (locoregional) (EMERALD-1) Regulatory submission (CN)
Imfinzi NSCLC (neoadjuvant) (AEGEAN) Regulatory submission
Imfinzi SCLC (limited-stage) (ADRIATIC) Regulatory submission
Lynparza +
Imfinzi Endometrial cancer (1st-line) (DUO-E) Data readout
Calquence CLL (ACE-CL-311) Data readout
Calquence MCL39 (1st-line) (ECHO) Data readout
capivasertib TNBC40 (locally adv./met.)
(CAPItello-290) Data readout, regulatory submission
camizestrant HR+/HER2-neg breast cancer (SERENA-6) Data readout
Farxiga Myocardial infarction (DAPA-MI) Data readout
Fasenra EGPA41 (MANDARA) Data readout
Fasenra HES42 (NATRON) Data readout
Soliris gMG Regulatory decision (CN)
Koselugo NF1-PN (SPRINT) Regulatory decision (CN)
ALXN1840 Wilson disease Regulatory submission
danicopan PNH with extravascular haemolysis Regulatory submission
38 Germline (hereditary) breast cancer gene mutation.
39 Mantle cell lymphoma.
40 Triple negative breast cancer.
41 Eosinophilic granulomatosis with polyangiitis.
42 Hyper-eosinophilic syndrome.
10
Contents
Operating and financial review………………………………………………………………………………………………………………….. 11
Total Revenue………………………………………………………………………………………………………………………………………… 12
Financial performance……………………………………………………………………………………………………………………………… 23
Profit and Loss drivers …………………………………………………………………………………………………………………………….. 25
Sustainability………………………………………………………………………………………………………………………………………….. 29
Research and development ……………………………………………………………………………………………………………………… 30
Interim financial statements ……………………………………………………………………………………………………………………… 35
Responsibility statement of the directors in respect of the half-yearly financial report……………………………………….. 40
Independent review report to AstraZeneca PLC………………………………………………………………………………………….. 41
Independent review report to AstraZeneca PLC………………………………………………………………………………………….. 42
Notes to the Interim financial statements……………………………………………………………………………………………………. 43
Other shareholder information ………………………………………………………………………………………………………………….. 53
Addresses for correspondence …………………………………………………………………………………………………………………. 54
Trademarks ……………………………………………………………………………………………………………………………………………. 54
AstraZeneca…………………………………………………………………………………………………………………………………………… 54
Cautionary statements regarding forward-looking statements……………………………………………………………………….. 55
List of tables
Table 1: Key elements of Total Revenue performance in Q2 2022 ………………………………………………………………….. 3
Table 2: Key elements of financial performance in Q2 2022 …………………………………………………………………………… 4
Table 3: Pipeline highlights since prior results announcement ………………………………………………………………………… 7
Table 4: Pipeline – anticipated major news flow…………………………………………………………………………………………….. 8
Table 5: Disease area and medicine performance ………………………………………………………………………………………. 12
Table 6: Collaboration Revenue………………………………………………………………………………………………………………… 13
Table 7: Total Revenue by disease area ……………………………………………………………………………………………………. 13
Table 8: Total Revenue by region……………………………………………………………………………………………………………… 13
Table 9: Total Revenue by region – excluding Vaxzevria……………………………………………………………………………… 13
Table 10: Reported Profit and Loss …………………………………………………………………………………………………………… 23
Table 11: Reconciliation of Reported Profit before tax to EBITDA………………………………………………………………….. 23
Table 12: Reconciliation of Reported to Core financial measures: H1 2022…………………………………………………….. 24
Table 13: Reconciliation of Reported to Core financial measures: Q2 2022 ……………………………………………………. 24
Table 14: Cash Flow summary …………………………………………………………………………………………………………………. 26
Table 15: Net Debt summary ……………………………………………………………………………………………………………………. 27
Table 16: Obligor group summarised Statement of comprehensive income ……………………………………………………. 28
Table 17: Obligor group summarised Statement of financial position information…………………………………………….. 28
Table 18: Currency sensitivities ………………………………………………………………………………………………………………… 28
Table 19: Condensed consolidated statement of comprehensive income – H1 2022 ……………………………………….. 35
Table 20: Condensed consolidated statement of comprehensive income – Q2 2022……………………………………….. 36
Table 21: Condensed consolidated statement of financial position ………………………………………………………………… 37
Table 22: Condensed consolidated statement of changes in equity……………………………………………………………….. 38
Table 23: Condensed consolidated statement of cash flows …………………………………………………………………………. 39
Table 24: Net Debt………………………………………………………………………………………………………………………………….. 44
Table 25: Financial instruments – contingent consideration…………………………………………………………………………… 45
Table 26: H1 2022 – Product Sales year-on-year analysis…………………………………………………………………………….. 51
Table 27: Q2 2022 – Product Sales year-on-year analysis (Unreviewed)………………………………………………………… 52
Table 28: Collaboration Revenue………………………………………………………………………………………………………………. 53
Table 29: Other Operating Income and Expense…………………………………………………………………………………………. 53
11
Operating and financial review
All narrative on growth and results in this section is based on actual exchange rates, and financial figures are
in US$ millions ($m), unless stated otherwise. Unless stated otherwise, the performance shown in this
announcement covers the six-month period to 30 June 2022 (‘the half’ or ‘H1 2022’) compared to the six-month
period to 30 June 2021 (H1 2021), or the three-month period to 30 June 2022 (‘the quarter’ or ‘Q2 2022’)
compared to the three-month period to 30 June 2021 (Q2 2021).
Core financial measures, EBITDA, Net Debt, CER, Initial Collaboration Revenue and Ongoing Collaboration
Revenue are non-GAAP financial measures because they cannot be derived directly from the Group’s Interim
financial statements. Management believes that these non-GAAP financial measures, when provided in
combination with Reported results, provide investors and analysts with helpful supplementary information to
understand better the financial performance and position of the Group on a comparable basis from period to
period. These non-GAAP financial measures are not a substitute for, or superior to, financial measures prepared
in accordance with GAAP.
Core financial measures are adjusted to exclude certain significant items, such as:
‒ Amortisation and impairment of intangible assets, including impairment reversals but excluding any charges
relating to IT assets
‒ Charges and provisions related to restructuring programmes, which includes charges that relate to the
impact of restructuring programmes on capitalised IT assets as well as Post Alexion Acquisition Group
Review items
‒ Alexion acquisition-related items, primarily fair-value adjustments on acquired inventories and fair-value
impact of replacement employee share awards
‒ Other specified items, principally the imputed finance charge relating to contingent consideration on business
combinations and legal settlements
‒ The tax effects of the adjustments above are excluded from the Core Tax charge
Details on the nature of Core financial measures are provided on page 54 of the Annual Report and Form 20-F
Information 2021.
Reference should be made to the Reconciliation of Reported to Core financial measures table included in the
financial performance section in this announcement.
Gross Margin, previously termed Gross Profit Margin, is the percentage by which Product Sales exceeds the
Cost of sales, calculated by dividing the difference between the two by the sales figure. The calculation of
Reported and Core Gross Margin excludes the impact of Collaboration Revenue and any associated costs,
thereby reflecting the underlying performance of Product Sales.
EBITDA is defined as Reported Profit Before Tax after adding back Net Finance Expense, results from Joint
Ventures and Associates and charges for Depreciation, Amortisation and Impairment. Reference should be
made to the Reconciliation of Reported Profit Before Tax to EBITDA included in the financial performance
section in this announcement.
Net Debt is defined as Interest-bearing loans and borrowings and Lease liabilities, net of Cash and cash
equivalents, Other investments, and net derivative financial instruments. Reference should be made to Note 3
‘Net Debt’ included in the Notes to the Interim financial statements in this announcement.
Ongoing Collaboration Revenue is defined as Collaboration Revenue excluding Initial Collaboration Revenue
(which is defined as Collaboration Revenue that is recognised at the date of completion of an agreement or
transaction, in respect of upfront consideration). Ongoing Collaboration Revenue comprises, among other
items, royalties, milestone revenue and profit-sharing income. Reference should be made to the Collaboration
Revenue table in this Operating and financial review.
The Company strongly encourages investors and analysts not to rely on any single financial measure, but to
review AstraZeneca’s financial statements, including the Notes thereto, and other available Company reports,
carefully and in their entirety.
Due to rounding, the sum of a number of dollar values and percentages in this announcement may not agree
to totals.
12
Total Revenue Financial Performance Sustainability Interim Financial Statements Research and Development
Total Revenue
Table 5: Disease area and medicine performance
H1 2022 Q2 2022
% Change % Change
Product Sales $m % Total Actual CER $m % Total Actual CER
Oncology 7,089 32 14 18 3,701 34 14 18
– Tagrisso 2,704 12 10 14 1,400 13 7 12
– Imfinzi 1,294 6 12 16 695 6 15 20
– Lynparza 1,291 6 14 18 673 6 15 20
– Calquence 903 4 84 87 489 5 74 77
– Enhertu 29 – >6x >6x 18 – >5x >5x
– Orpathys 23 – n/m n/m 11 – n/m n/m
– Zoladex 477 2 2 7 236 2 (3) 2
– Faslodex 178 1 (21) (16) 86 1 (18) (11)
– Iressa 63 – (41) (39) 32 – (32) (29)
– Arimidex 61 – (17) (13) 28 – (1) 5
– Casodex 42 – (49) (47) 21 – (50) (48)
– Others 24 – (4) 3 12 – (8) 1
BioPharmaceuticals: CVRM8 4,559 21 14 18 2,352 22 14 19
– Farxiga 2,103 9 55 63 1,103 10 51 59
– Brilinta 675 3 (10) (7) 350 3 (7) (4)
– Lokelma 129 1 79 87 66 1 68 79
– Roxadustat 91 – 1 1 50 – (2) (1)
– Andexxa8 70 – 9 12 37 – 5 11
– Crestor 547 2 2 6 280 3 6 11
– Seloken/Toprol-XL 467 2 (9) (7) 223 2 (16) (13)
– Bydureon 141 1 (29) (28) 73 1 (23) (22)
– Onglyza 139 1 (31) (28) 71 1 (28) (25)
– Others 197 1 (9) (7) 99 1 (1) 1
BioPharmaceuticals: R&I 2,891 13 (2) – 1,381 13 (3) 1
– Symbicort 1,288 6 (6) (3) 614 6 (10) (6)
– Fasenra 662 3 14 18 354 3 11 15
– Breztri 179 1 >2x >2x 93 1 66 72
– Saphnelo 36 – n/m n/m 24 – n/m n/m
– Pulmicort 334 2 (33) (32) 116 1 (30) (28)
– Daliresp 109 – (5) (4) 58 1 7 8
– Bevespi 30 – 13 16 15 – 12 17
– Others 253 1 (13) (12) 107 1 (18) (17)
BioPharmaceuticals: V&I 2,734 12 >2x >2x 977 9 10 15
– Vaxzevria 1,540 7 36 41 451 4 (48) (44)
– Evusheld 914 4 n/m n/m 445 4 n/m n/m
– Synagis 280 1 >5x >6x 80 1 >3x >3x
– FluMist – – n/m n/m 1 – n/m n/m
Rare Disease8 3,495 16 5 10 1,801 17 6 12
– Soliris8 2,017 9 (5) 1 1,027 10 (5) 2
– Ultomiris8 853 4 22 28 434 4 23 31
– Strensiq8 450 2 11 13 242 2 16 18
– Koselugo 101 – >2x >2x 62 1 >2x >2x
– Kanuma8 74 – 9 14 36 – 9 13
Other Medicines 842 4 (11) (6) 418 4 (3) 6
– Nexium 674 3 (9) (2) 343 3 2 12
– Others 168 1 (21) (20) 75 1 (19) (17)
Product Sales 21,610 98 41 47 10,630 99 32 38
Collaboration Revenue 551 2 >2x >2x 141 1 (20) (20)
Total Revenue 22,161 100 43 48 10,771 100 31 37
13
Total Revenue Financial Performance Sustainability Interim Financial Statements Research and Development
Table 6: Collaboration Revenue
H1 2022 Q2 2022
% Change % Change
$m % Total Actual CER $m % Total Actual CER
Lynparza: regulatory milestones 175 32 n/m n/m – – n/m n/m
Enhertu: share of gross profits 173 31 >2x >2x 99 70 >2x >2x
Tezspire: share of gross profits 16 3 n/m n/m 13 9 n/m n/m
Vaxzevria: royalties 60 11 83 77 4 3 (87) (88)
Tralokinumab: sales milestone 70 13 n/m n/m – – n/m n/m
Other royalty income 37 7 2 2 20 14 7 9
Other Collaboration Revenue 20 4 (77) (77) 5 4 (93) (93)
Total 551 100 >2x >2x 141 100 (20) (20)
Table 7: Total Revenue by disease area
H1 2022 Q2 2022
% Change % Change
$m % Total Actual CER $m % Total Actual CER
Oncology 7,454 34 18 22 3,810 35 15 20
BioPharmaceuticals 10,350 47 26 31 4,733 44 8 13
– CVRM 4,576 21 14 19 2,356 22 14 19
– R&I 2,979 13 – 3 1,395 13 (2) 1
– V&I 2,795 13 >2x >2x 981 9 7 12
Rare Disease 3,495 16 5 10 1,801 17 6 12
Other Medicines 862 4 (18) (12) 427 4 (17) (10)
Total 22,161 100 43 48 10,771 100 31 37
Table 8: Total Revenue by region
H1 2022 Q2 2022
% Change % Change
$m % Total Actual CER $m % Total Actual CER
Emerging Markets 6,156 28 13 16 2,792 26 (3) 1
– China 3,057 14 (5) (5) 1,435 13 (6) (5)
– Ex-China 3,099 14 38 46 1,357 13 1 7
US 8,482 38 75 75 4,348 40 72 72
Europe 4,364 20 34 45 2,080 19 21 35
Established RoW 3,159 14 59 74 1,551 14 39 55
Total 22,161 100 43 48 10,771 100 31 37
Table 9: Total Revenue by region – excluding Vaxzevria
H1 2022 Q2 2022
% Change % Change
$m % Total Actual CER $m % Total Actual CER
Emerging Markets 5,436 25 9 13 2,603 24 7 11
– China 3,011 14 (6) (7) 1,435 13 (6) (5)
– Ex-China 2,425 11 38 48 1,167 11 31 39
US 8,403 38 74 74 4,348 40 72 72
Europe 4,102 19 53 66 1,952 18 43 59
Established RoW 2,620 12 40 53 1,412 13 39 56
Total 20,561 93 43 48 10,316 96 41 47
14
Total Revenue Financial Performance Sustainability Interim Financial Statements Research and Development
Oncology
Oncology Total Revenue increased by 18% (22% at CER) in H1 2022 to $7,454m and represented 34% of
overall Total Revenue (H1 2021: 41%). This included Lynparza Collaboration Revenue of $175m (H1 2021:
$nil) and Enhertu Collaboration Revenue of $175m (H1 2021: $85m). Product Sales increased by 14% (18% at
CER) in H1 2022 to $7,089m, reflecting new launches and increased patient access for Tagrisso, Imfinzi,
Lynparza and Calquence partially offset by declines in legacy medicines.
Overall rates of cancer diagnosis, testing and treatment in the half continued to show a cumulative impact from
the COVID-19 pandemic with rates in CLL, lung cancer and ovarian cancer remaining below pre-COVID-19
baseline, with some signs of improvement. Rates of breast cancer diagnosis in the US appear to be approaching
normal levels. In China, COVID-19 related lockdowns in several major cities had an adverse impact during the
second quarter.
Tagrisso
Total Revenue Worldwide Emerging Markets US Europe Established RoW
H1 2022 $m 2,704 805 951 509 439
Actual change 10% 16% 11% 9% 1%
CER change 14% 17% 11% 19% 12%
Region Drivers and commentary
Worldwide Increased use of Tagrisso in adjuvant and 1st-line setting
Emerging Markets Increased 1st-line use in China and continued growth in other Emerging Markets
Rising demand from increased patient access in China continues to offset the impact of the
March 2021 NRDL price reduction
In China, COVID-19 related lockdowns in several major cities had an adverse impact
US Increasing EGFR testing rates.
Greater use in 1st-line
Strong adjuvant launch momentum
Europe Greater use in 1st-line and adjuvant settings, with longer duration of treatment, partially offset
by lower 2nd-line use
Established RoW Increased use in 1st-line setting and launch progress in adjuvant
Imfinzi
Total Revenue Worldwide Emerging Markets US Europe Established RoW
H1 2022 $m 1,294 134 689 267 204
Actual change 12% 1% 15% 18% 1%
CER change 16% 2% 15% 29% 12%
Region Drivers and commentary
Worldwide Increased use of Imfinzi to treat patients with ES-SCLC43, offset by impact from lower rates
of diagnosis and treatment due to the ongoing COVID-19 pandemic
Emerging Markets Growth in ex-China, offset by an adverse impact in CRT44 rates and hospital use of infused
oncology medicines due to COVID-19 lockdowns in several major cities in China during the
period
US New patient starts across Stage III NSCLC and ES-SCLC
Europe Increased market penetration in ES-SCLC, growth in the number of reimbursed markets,
offsetting the impact of COVID-19 on rates of diagnosis and treatment
Established RoW New reimbursements
43 Extensive-stage small cell lung cancer.
44 Chemoradiation therapy.
15
Total Revenue Financial Performance Sustainability Interim Financial Statements Research and Development
Lynparza
Total Revenue Worldwide Emerging Markets US Europe Established RoW
H1 2022 $m 1,466 241 582 504 139
Actual change 30% 30% 11% 67% 15%
CER change 34% 32% 11% 78% 27%
Product Sales Worldwide Emerging Markets US Europe Established RoW
H1 2022 $m 1,291 241 582 329 139
Actual change 14% 30% 11% 9% 15%
CER change 18% 32% 11% 20% 27%
Region Drivers and commentary
Worldwide Lynparza remains the leading medicine in the PARP45
-inhibitor class globally across four
tumour types, as measured by total prescription volume
Total Revenue includes a $175m regulatory milestone received from MSD and recognised in
Europe, in respect of the approval in the US for the adjuvant treatment of patients with breast
cancer, based on the data from the OlympiA Phase III trial
Emerging Markets Increased patient access following admission to China’s NRDL as a 1st-line treatment for
ovarian cancer patients, with effect from March 2021; also launches in other markets
In China, COVID-19-related lockdowns in several major cities had an adverse impact
US US launch in early breast cancer following US FDA46 approval in March based on data from
the OlympiA Phase III trial
Growth in use in ovarian and prostate cancers
Europe Reimbursements introduced in additional countries, increasing BRCAm-testing rates, and
successful launches in 1st-line BRCAm ovarian, 2nd-line HRRm47 prostate and gBRCAm
HER2-negative advanced breast cancer
Established RoW New product launches and high levels of HRD
48 testing in Japan
Enhertu
Total Revenue Worldwide Emerging Markets US Europe Established RoW
H1 2022 $m 204 26 130 46 2
Actual change >2x >6x 72% >4x n/m
CER change >2x >6x 72% >4x n/m
Region Drivers and commentary
Worldwide Excluding Japan, Enhertu global in-market sales recorded by Daiichi Sankyo Company
Limited (Daiichi Sankyo) and AstraZeneca, amounted to $397m in the half (H1 2021: $183m)
AstraZeneca’s Total Revenue of $204m includes $175m of Collaboration Revenue from its
share of gross profit in territories where Daiichi Sankyo records product sales
Emerging Markets Strong uptake in early launch markets
US US in-market sales, recorded by Daiichi Sankyo, amounted to $274m in the half
(H1 2021: $161m)
US launch in 2nd-line HER2-positive metastatic breast cancer after US FDA approval in May
based on data from the DESTINY-Breast03 Phase III trial
Europe Growth in 3rd-line+ HER2-positive metastatic breast cancer in large European markets
ESMO (Free ESMO Whitepaper) guidelines updated in late 2021 to include Enhertu use in 2nd-line
Established RoW In Japan, AstraZeneca receives a mid-single-digit percentage royalty on sales made by
Daiichi Sankyo
45 Poly ADP ribose polymerase.
46 US Food and Drug Administration.
47 Homologous recombination repair gene mutation.
48 Homologous recombination deficiency.
16
Total Revenue Financial Performance Sustainability Interim Financial Statements Research and Development
Calquence
Total Revenue Worldwide Emerging Markets US Europe Established RoW
H1 2022 $m 903 16 735 122 30
Actual change 84% >2x 65% >3x >4x
CER change 87% >2x 65% >4x >5x
Region
US Increased new patient market share led to a strong performance, despite continued
COVID-19 impacts on CLL diagnosis rates
Europe Increased market share in new patient starts after launches in the region
Orpathys
Orpathys Total Revenue of $24m in the half (H1 2021: $nil) was driven by the 2021 launch in China, where it is
approved for patients with lung cancer and MET49 gene alterations.
Other Oncology medicines
H1 2022 % Change
Total Revenue $m Actual CER
Zoladex 491 3% 8% Increased use in ex-China Emerging Markets, offsetting a price cut
in Japan
Faslodex 178 (21%) (16%) Generic competition
Iressa 63 (41%) (39%) Continued share loss to next generation TKI50s
Arimidex 61 (17%) (13%)
Casodex 42 (49%) (47%) Ongoing impact from VBP implementation
Other Oncology 24 (4%) 3%
BioPharmaceuticals
Including Vaccines & Immune Therapies medicines, BioPharmaceuticals Total Revenue increased by 26%
(31% at CER) in H1 2022 to $10,350m, representing 47% of overall Total Revenue (H1 2021: 53%). Growth
was driven by strong Farxiga performance and growth in the COVID-19 medicines.
Cardiovascular, Renal & Metabolism
Total Revenue from CVRM medicines increased by 14% (19% at CER) in H1 2022, driven by a strong Farxiga
performance, to $4,576m and represented 21% of overall Total Revenue (H1 2021: 25%).
49 Mesenchymal-epithelial transition.
50 Tyrosine kinase inhibitor.
17
Total Revenue Financial Performance Sustainability Interim Financial Statements Research and Development
Farxiga
Total Revenue Worldwide Emerging Markets US Europe Established RoW
H1 2022 $m 2,105 814 468 627 197
Actual change 55% 46% 55% 69% 54%
CER change 62% 50% 55% 85% 68%
Region
Worldwide Farxiga volume is growing faster than the overall SGLT251 market in most major regions
Growth in the SGLT2 inhibitor class
Further HF52 and CKD launches and updated treatment guidelines including from ESC53 and
AHA54/ACC55/HFSA
56
Emerging Markets uACR57 and MRF58 testing programs in China, and solid growth in ex-China Emerging
Markets, particularly Latin America
In China, Forxiga’s NRDL status was renewed in the fourth quarter of 2021
US Regulatory approval for HFrEF59 in May 2020, treatment of CKD in May 2021, and
favourable gross-to-net adjustments
Both approvals included patients with and without T2D60
Farxiga continued to gain in-class brand share, driven by HF and CKD launches
Europe The beneficial addition of cardiovascular outcomes trial data to the label, the HFrEF
regulatory approval in November 2020, and CKD regulatory approval in August 2021
Forxiga continued gains in-class market share in the period
Established RoW In Japan, sales to collaborator Ono Pharmaceutical Co., Ltd, which records in-market sales,
were $134m (H1 2021: $71m)
Brilinta
Total Revenue Worldwide Emerging Markets US Europe Established RoW
H1 2022 $m 675 146 351 150 28
Actual change (10%) (19%) (2%) (16%) (12%)
CER change (7%) (15%) (2%) (8%) (8%)
Region
Emerging Markets Adverse impact from Brilinta’s inclusion in China’s VBP programme
Strong growth in ex-China Emerging Markets
US, Europe Fewer elective procedures due to the effects of the pandemic
Lokelma
Total Revenue increased 79% (87% at CER) to $129m in H1, driven by Lokelma extending its branded market
share lead in the US and also achieving total market share leadership in the period. Continued progress in
Europe from recent launches across the region. In China, Lokelma was included on the NRDL with effect from
1 January 2022.
Andexxa
On a pro forma basis, Total Revenue increased 25% (28% at CER) to $80m. Andexxa launched in Japan in
May 2022.
51 Sodium-glucose cotransporter 2.
52 Heart failure.
53 European Society of Cardiology.
54 American Heart Association.
55 American College of Cardiology.
56 Heart Failure Society of America.
57 Urine albumin creatine ratio.
58 Measured renal function.
59 Heart failure with reserved ejection fraction.
60 Type-2 diabetes.
18
Total Revenue Financial Performance Sustainability Interim Financial Statements Research and Development
Roxadustat
Total Revenue increased 1% to $94m. Total Revenue also increased quarter-on-quarter, with roxadustat
benefitting from increased volumes in China following NRDL price cuts.
Other CVRM medicines
H1 2022 % Change
Total Revenue $m Actual CER
Crestor 548 2% 6% Sales growth driven in Emerging Markets, offset by declines in the
US and Europe
Seloken 468 (9%) (7%) Emerging Markets sales impacted by China VBP implementation of
Betaloc61 oral in H2 2021. Betaloc ZOK VBP to be implemented
later in 2022
Onglyza 139 (31%) (28%) Ongoing impact from VBP implementation
Bydureon 141 (29%) (28%) Continued competitive pressures
Other CVRM 197 (9%) (7%)
Respiratory & Immunology
Total Revenue from R&I medicines was stable in H1 2022 (increased 3% at CER) at $2,979m and represented
13% of overall Total Revenue (H1 2021: 19%).
Symbicort
Total Revenue Worldwide Emerging Markets US Europe Established RoW
H1 2022 $m 1,288 306 481 312 189
Actual change (6%) – (9%) (9%) (1%)
CER change (3%) 3% (9%) (1%) 4%
Region
Worldwide Symbicort remains the global market leader within the ICS62/LABA63 class
The global ICS/LABA market continues to be eroded as fixed-dose triple therapies
(LAMA64/LABA/ICS) continue to launch in major markets (US, China and Japan)
Emerging Markets Growth in Ex-China Emerging Markets
Continued impact of fixed-dose triple therapy launches and COVID-19 restrictions in China
US Maintained market share and leadership in a declining ICS/LABA market as fixed-dose triple
therapy launches continue
Unfavourable gross-to-net adjustment during the second quarter
Established RoW Sales in Japan continued to decline due to continued generic erosion as well as the annual
mandatory price reduction, which occurred in April
61 Betaloc is the brand name for Seloken in China.
62 Inhaled corticosteroid.
63 Long-acting beta-agonist.
64 Long-acting muscarinic-agonist.
19
Total Revenue Financial Performance Sustainability Interim Financial Statements Research and Development
Fasenra
Total Revenue Worldwide Emerging Markets US Europe Established RoW
H1 2022 $m 662 17 419 153 73
Actual change 14% >2x 18% 12% (8%)
CER change 18% >2x 18% 23% 1%
Region
Worldwide Fasenra continued to lead the IL-5 class, in severe eosinophilic asthma, in major markets
(US, Japan and some EU countries)
US Maintained a stable new-to-brand share of the severe uncontrolled asthma class
Europe Growth driven by increased market share performance
Established RoW Increased demand and sustained leadership in new-to-brand prescriptions in Japan, offset
by the mandatory price reduction, which took effect in April
Breztri
Total Revenue Worldwide Emerging Markets US Europe Established RoW
H1 2022 $m 179 43 106 14 16
Actual change >2x 61% >2x >10x 46%
CER change >2x 61% >2x >10x 65%
Region
Worldwide Breztri continued to gain market share within the fixed-dose triple class in major markets
Emerging Markets Continued its market share leadership within the fixed-dose triple class in China, which
continues to gain share from the ICS/LABA class
COVID-19 restrictions impacted inhaled maintenance market growth
US Increased new-to-brand market share within the fixed-dose triple class
Europe Sustained growth across markets as new launches continue to progress
Established RoW Strong launch performance in Japan
Saphnelo
Total Revenue of $36m in the half (H1 2021: $nil) was driven by the 2021 launch in the US, where Saphnelo
has been approved for SLE65 and received a permanent J-code facilitating reimbursement. In Japan, there was
an adverse impact as COVID-19 lockdowns limited access to hospitals.
Tezspire
Total Revenue of $16m in the half (H1 2021: $nil) was comprised entirely of Collaboration Revenue and
reflected the US launch of Tezspire as add-on maintenance treatment for patients with severe asthma following
US FDA approval in December 2021. Amgen records sales in the US and AstraZeneca records its share of
gross profits in the US as Collaboration Revenue. US in-market sales were $36m.
65 Systemic lupus erythematosus.
20
Total Revenue Financial Performance Sustainability Interim Financial Statements Research and Development
Other R&I medicines
H1 2022 % Change
Total Revenue $m Actual CER
Pulmicort 334 (33%) (32%) Revenue from Emerging Markets decreased 42% (41% at CER) to
$236m, impacted by VBP implementation in China and lower rates
of elective surgery and limited access to nebulisation centres due to
COVID-19 lockdowns
Daliresp 109 (5%) (4%)
Bevespi 30 13% 16%
Other R&I 326 9% 9%
Vaccines & Immune Therapies
Total Revenue from Vaccines & Immune Therapies medicines increased to $2,795m (H1 2021: $1,221m) and
represented 13% of overall Total Revenue (H1 2021: 8%).
Vaxzevria
Total Revenue Worldwide Emerging Markets US Europe Established RoW
H1 2022 $m 1,600 720 80 262 538
Actual change 37% 47% n/m (54%) >4x
CER change 42% 47% n/m (50%) >5x
Region
Worldwide The majority of Vaxzevria revenue in H1 2022 came from initial, not-for-profit contracts
Revenue in the second quarter decreased by 49% (46% at CER)
Emerging Markets Growth was driven by initial and commercial contracts in Latin America and Asia
$46m of Collaboration Revenue came from a Chinese sub-licensee producing vaccines for
export
Revenue in the second quarter decreased by 57%
US Purchases by the US government for donation overseas
No revenue recorded in the second quarter
Europe Revenue in the second quarter decreased by 63% (59% at CER)
Established RoW Sales in Japan, Canada and Australia
Revenue in the second quarter increased by 36% (50% at CER)
Evusheld
Total Revenue Worldwide Emerging Markets US Europe Established RoW
H1 2022 $m 914 93 556 143 122
Actual change n/m n/m n/m n/m n/m
CER change n/m n/m n/m n/m n/m
Region
US Evusheld received Emergency Use Authorisation for prevention of COVID-19 in December
2021
In H1 2022, AstraZeneca continued fulfilment of the US Government’s order for 1.7m units.
The remainder of that order is expected to be fulfilled before the end of 2022
Emerging Markets Multiple government contracts in Central and Eastern Europe, Latin America and South East
Asia and China. Evusheld is the first non-Chinese medicine to be used for the prevention of
COVID-19 in China
Europe Approved in the EU for prevention of COVID-19 in March 2022
21
Total Revenue Financial Performance Sustainability Interim Financial Statements Research and Development
Other V&I medicines
H1 2022 % Change
Total Revenue $m Actual CER
Synagis 280 >5x >6x The year-on-year increase reflects the reversion of ex-US rights to
AstraZeneca following expiry of the collaboration agreement with
AbbVie Inc. on 30 June 2021
FluMist – n/m n/m Normal seasonality of FluMist sales
Rare Disease
On a pro forma basis, Total Revenue from Rare Disease medicines increased by 5% (10% at CER) in H1 2022
to $3,495m. In H1 2022, Rare Disease represented 16% of overall Total Revenue. Excluding a one-off historic
pricing adjustment that benefited ex-US Total Revenue in the second quarter, Rare Disease pro forma revenue
growth would have been 2% (8% at CER). Performance was driven by continued conversion from Soliris to
Ultomiris, and initial uptake of Ultomiris in gMG following US launch. Strensiq and Koselugo performances were
driven by patient growth and market expansion respectively.
These tables show pro forma growth rates for the medicines acquired with Alexion, calculated by comparing H1
2022 revenues with the revenues to 30 June 2021 as reported by Alexion.
Soliris
Total Revenue Worldwide Emerging Markets US Europe Established RoW
H1 2022 $m 2,017 134 1,165 437 281
Actual change8
(5%) (45%) 2% (17%) 34%
CER change8 1% (29%) 2% (8%) 46%
Region
US Growth in neurology indications (gMG and NMOSD), offset by continued conversion from
Soliris to Ultomiris
Ex-US Performance driven by neurology growth in new markets and a one-off adjustment in the
second quarter
Ultomiris
Total Revenue Worldwide Emerging Markets US Europe Established RoW
H1 2022 $m 853 30 456 225 142
Actual change8 22% >6x 10% 65% (3%)
CER change8 28% >6x 10% 81% 11%
Region
Worldwide Continued conversion from Soliris to Ultomiris and expansion into new markets
Quarter-on-quarter revenue growth variability can be expected due to Ultomiris every eightweek dosing schedule and lower average annual treatment cost per patient compared to
Soliris
US Continued conversion and patient growth in PNH and aHUS, as well as initial uptake
following recent gMG approval and launch
Ex-US Accelerated conversion in newly-launched markets
22
Total Revenue Financial Performance Sustainability Interim Financial Statements Research and Development
Other Rare Disease medicines
H1 2022 % Change
Total Revenue $m Actual CER Commentary
Strensiq8 450 11% 13% Performance driven by demand growth and one-time benefit from
timing of inventory dynamics
Koselugo 101 >2x >2x Performance driven by expansion in the US and new markets, as
well as timing of certain ex-US tender market orders
Kanuma8 74 9% 14% Continued demand growth in ex-US markets
Other medicines (outside the main disease areas)
H1 2022 % Change
Total Revenue $m Actual CER Commentary
Nexium 685 (17%) (11%) Nexium (oral) was included in China’s VBP programme
implemented in February 2021 and Nexium (i.v.66) was implemented
in the fifth round of VBP in October 2021
Others 177 (20%) (19%)
66 Intravenous injection.
23
Total Revenue Financial Performance Sustainability Interim Financial Statements Research and Development
Financial performance
Table 10: Reported Profit and Loss
H1 2022 H1 2021 % Change Q2 2022 Q2 2021 % Change
$m $m Actual CER $m $m Actual CER
Total Revenue 22,161 15,540 43 48 10,771 8,220 31 37
– Product Sales 21,610 15,302 41 47 10,630 8,045 32 38
– Collaboration Revenue 551 238 n/m n/m 141 175 (20) (20)
Cost of Sales (6,509) (4,055) 61 71 (2,998) (2,191) 37 49
Gross Profit 15,652 11,485 36 40 7,773 6,029 29 33
Gross Margin 69.9% 73.5% -4 -4 71.8% 72.8% -1 -2
Distribution Expense (254) (202) 26 32 (129) (103) 25 33
% Total Revenue 1.1% 1.3% – – 1.2% 1.3% – –
R&D Expense (4,679) (3,542) 32 35 (2,546) (1,829) 39 44
% Total Revenue 21.1% 22.8% 2 2 23.6% 22.2% -1 -1
SG&A Expense (9,521) (6,027) 58 62 (4,681) (3,098) 51 56
% Total Revenue 43.0% 38.8% -4 -4 43.5% 37.7% -6 -5
OOI67 & Expense 219 1,308 (83) (83) 122 128 (5) (5)
% Total Revenue 1.0% 8.4% -7 -7 1.1% 1.6% – –
Operating Profit 1,417 3,022 (53) (49) 539 1,127 (52) (53)
Operating Margin 6.4% 19.4% -13 -13 5.0% 13.7% -9 -9
Net Finance Expense (612) (602) 2 9 (293) (319) (8) 10
Joint Ventures and Associates (5) (48) (90) (88) 1 (44) n/m n/m
Profit before tax 800 2,372 (66) (62) 247 764 (68) (75)
Taxation (52) (260) (80) (77) 113 (214) n/m n/m
Tax rate 7% 11% -46% 28%
Profit after tax 748 2,112 (65) (60) 360 550 (35) (37)
Earnings per share $0.48 $1.61 (70) (66) $0.23 $0.42 (45) (46)
Table 11: Reconciliation of Reported Profit before tax to EBITDA
H1 2022 H1 2021 % Change Q2 2022 Q2 2021 % Change
$m $m Actual CER $m $m Actual CER
Reported Profit before tax 800 2,372 (66) (62) 247 764 (68) (75)
Net Finance Expense 612 602 2 9 293 319 (8) 10
Joint Ventures and Associates 5 48 (90) (88) (1) 44 n/m n/m
Depreciation, Amortisation and
Impairment 2,666 1,550 72 73 1,357 753 80 82
EBITDA 4,083 4,572 (11) (8) 1,896 1,880 1 1
EBITDA of $4,083m in the half (H1 2021: $4,572m) has been negatively impacted by the $2,318m (H1
2021: $nil) unwind of inventory fair value uplift recognised on the acquisition of Alexion. EBITDA of $1,896m in
the quarter (Q2 2021: $1,880m) has been negatively impacted by the $1,138m (Q2 2021: $nil) unwind of
inventory fair value uplift recognised on the acquisition of Alexion. The unwind of inventory fair value is expected
to depress EBITDA over the year in line with associated revenues.
67 Other Operating Income.
24
Total Revenue Financial Performance Sustainability Interim Financial Statements Research and Development
Table 12: Reconciliation of Reported to Core financial measures: H1 2022
H1 2022 Reported Restructuring
Intangible Asset
Amortisation &
Impairments
Acquisition
of Alexion Other Core Core
% Change
$m $m $m $m $m $m Actual CER
Gross Profit 15,652 81 16 2,320 – 18,069 57 60
Gross Margin 69.9% 81.1% +7pp +6pp
Distribution
Expense (254) 1 – – – (253) 25 32
R&D Expense (4,679) 38 6 18 – (4,617) 34 38
SG&A Expense (9,521) 198 2,081 30 1,12968 (6,083) 25 29
Total Operating
Expense (14,454) 237 2,087 48 1,129 (10,953) 29 33
Other Operating
Income & Expense 219 (9) – – – 210 (84) (84)
Operating Profit 1,417 309 2,103 2,368 1,129 7,326 69 71
Operating Margin 6.4% 33.1% +5pp +4pp
Net Finance
Expense (612) – – 137 (475) 16 24
Taxation (52) (61) (387) (546) (207) (1,253) n/m n/m
EPS $0.48 $0.16 $1.10 $1.18 $0.69 $3.61 43 44
Table 13: Reconciliation of Reported to Core financial measures: Q2 2022
Q2 2022 Reported Restructuring
Intangible Asset
Amortisation &
Impairments
Acquisition
of Alexion Other Core Core
% Change
$m $m $m $m $m $m Actual CER
Gross Profit 7,773 30 8 1,139 – 8,950 48 52
Gross Margin 71.8% 82.9% +10pp +8pp
Distribution
Expense (129) – – – – (129) 25 33
R&D Expense (2,546) 33 75 7 – (2,431) 35 40
SG&A Expense (4,681) 181 983 13 367 (3,137) 27 33
Total Operating
Expense (7,356) 214 1,058 20 367 (5,697) 30 36
Other Operating
Income & Expense 122 (10) – – – 112 (12) (13)
Operating Profit 539 234 1,066 1,159 367 3,365 86 87
Operating Margin 5.0% 31.2% +9pp +8pp
Net Finance
Expense (293) – – – 70 (223) 1 26
Taxation 113 (46) (196) (266) (86) (481) 32 28
EPS $0.23 $0.12 $0.56 $0.58 $0.23 $1.72 92 89
68 Other SG&A expense of $1,129m predominantly includes the $775m charge to provisions relating to the legal settlement with Chugai
and $293m of fair value movements on contingent consideration arising from business combinations.
25
Total Revenue Financial Performance Sustainability Interim Financial Statements Research and Development
Profit and Loss drivers
Gross Profit
‒ The Gross Profit Margin (Reported and Core) in the half was impacted by:
‒ Positive mix effects: the increased contribution from Rare Disease and Oncology medicines had a
positive impact on the Gross Margin
‒ Negative mix effects: sales of Vaxzevria and medicines with profit-sharing arrangements (primarily
Lynparza) had a dilutive impact on the Gross Margin. In the second quarter, there was less dilution from
Vaxzevria than in previous quarters, due to phasing on Vaxzevria contracts that were fulfilled in the
quarter
‒ Pricing pressure relating to the VBP and NRDL procurement programmes in China
‒ Reported Gross Profit was also impacted by the unwind of the fair value adjustment to Alexion inventories
at the date of acquisition. The fair value uplift is expected to unwind through Reported Cost of Sales over
2022 in line with associated revenues, and in H1 2022, the impact of the fair value uplift unwind on Cost of
Sales was $2,318m
‒ Currency fluctuations had a positive impact in the first half. Currency fluctuations may have a positive or
negative impact on Gross Margin in future quarters
‒ Variations in Gross Margin performance between periods can be expected to continue
R&D Expense
‒ The increase in Reported and Core R&D Expense was driven by:
‒ The acquisition of Alexion in July 2021
‒ Recent positive data read outs for several high priority medicines that ungated late-stage Oncology
trials
‒ The advancement of a number of Phase II clinical development programmes in BioPharmaceuticals
‒ Investment in platforms, new technology and capabilities to enhance R&D productivity
‒ A one-off $89m impairment of a pre-paid asset relating to a discontinued collaboration with an external
partner
‒ Reported R&D Expense in H1 2022 was also impacted by intangible asset impairment reversals
SG&A Expense
‒ The increase in Reported and Core SG&A Expense was driven by:
‒ The acquisition of Alexion
‒ Market development activities for recent launches, including Evusheld
‒ Reported SG&A Expense was also impacted by amortisation of intangible assets related to the Alexion
acquisition and a $775m legal settlement with Chugai
Other Operating Income
‒ Other Operating Income of $219m consisted primarily of royalties and disposal proceeds on small
divestments, including the divestment of rights to Plendil in the second quarter
‒ In H1 2021, Other Operating Income of $1,308m included $776m of divestment gains from AstraZeneca’s
share of Viela Bio, Inc. and $309m from the commercial rights to Crestor in over 30 countries in Europe
(excluding UK and Spain)
Net Finance Expense
‒ The increase in Net Finance Expense in the half was driven by financing costs on debt for the Alexion
transaction, increased interest on tax, and currency fluctuations
26
Total Revenue Financial Performance Sustainability Interim Financial Statements Research and Development
Taxation
‒ Reported Tax rate is lower than H1 2021 and Core Tax rate is higher than H1 2021. Reported tax rate is
lower due to impact of non-core charges on the level of Reported Profit Before Tax in H1 2022 and both
Reported and Core Tax rates were impacted by one-off items in 2021, including the non-taxable gain on the
divestment of Viela and updates to estimates of prior period tax liabilities following settlements with tax
authorities
‒ The net cash paid for the half was $1,006m (H1 2021: $869m) representing 126% of Reported Profit Before
Tax (H1 2021: 37%). The cash tax rate increased due to the impact of Non-core charges on the level of
Reported Profit Before Tax and effects of US rules around deferral of tax relief on R&D costs
‒ The Reported Tax rate of 7% was lower than Core Tax rate of 18% due to the impact of Non-Core charges
on the level of Reported Profit Before Tax. Q2 2022 Reported and Core Tax rates also benefited from the
geographical mix of profits and favourable adjustments to prior year tax liabilities in a number of major
jurisdictions in the quarter
‒ On 20 July 2022, the UK Government issued draft legislation in relation to the new global minimum tax
framework, expected to be brought into effect in the UK from 2024. The Company is currently assessing
potential impact of these draft rules upon its financial statements.
Dividend
‒ Interim dividend declared of $0.93 (76.4 pence, 9.49 SEK) per ordinary share
Table 14: Cash Flow summary
H1 2022 H1 2021 Change
$m $m $m
Reported Operating Profit 1,417 3,022 (1,605)
Depreciation, Amortisation and Impairment 2,666 1,550 1,116
Decrease in Working Capital and Short-term Provisions 2,391 857 1,534
Gains on Disposal of Intangible Assets (81) (354) 273
Gains on Disposal of Investments in Associates and Joint Ventures – (776) 776
Fair value movements on contingent consideration arising from
business combinations 293 82 211
Non-Cash and Other Movements (814) (363) (451)
Interest Paid (386) (323) (63)
Taxation Paid (1,006) (869) (137)
Net Cash Inflow from Operating Activities 4,480 2,826 1,654
Net Cash Inflow before Financing Activities 3,512 3,145 367
Net Cash (Outflow)/Inflow from Financing Activities (5,035) 4,558 (9,593)
The increase in Net Cash Inflow from Operating Activities of $1,654m primarily reflected an underlying
improvement in business performance, including the contribution from Alexion.
The Reported Operating Profit of $1,417m in the period includes a negative impact of $2,318m relating to the
unwind of the inventory fair value uplift recognised on the acquisition of Alexion. This is offset by a corresponding
item (positive impact of $2,318m) in Decrease in Working Capital and Short-term Provisions. Overall, the unwind
of the fair value uplift has no impact on Net Cash Inflow from Operating Activities.
The change in Working Capital and Short-term Provisions of $1,534m, whilst being positively impacted by the
aforementioned inventory fair value uplift unwind, has been adversely impacted by the reduction of Vaxzevria
working capital balances predominantly within Trade and other payables.
Capital Expenditure
Capital Expenditure amounted to $472m in the half (H1 2021: $508m). The Company anticipates an increase
in Capital Expenditure relative to FY 2021, partly driven by an expansion in its capacity for growth and the
acquisition of Alexion.
27
Total Revenue Financial Performance Sustainability Interim Financial Statements Research and Development
Table 15: Net Debt summary
At 30
Jun 2022
At 31
Dec 2021
At 30
Jun 2021
$m $m $m
Cash and cash equivalents 4,817 6,329 15,567
Other investments 70 69 62
Cash and investments 4,887 6,398 15,629
Overdrafts and short-term borrowings (747) (387) (560)
Lease liabilities (905) (987) (690)
Current instalments of loans (1,415) (1,273) (2,136)
Non-current instalments of loans (26,461) (28,134) (24,109)
Interest-bearing loans and borrowings (Gross Debt) (29,528) (30,781) (27,495)
Net derivatives (48) 61 145
Net Debt (24,689) (24,322) (11,721)
Net Debt increased by $367m in the half to $24,689m. Details of the committed undrawn bank facilities are
disclosed within the going concern section of Note 1. Details of the Company’s solicited credit ratings are
disclosed in Note 3.
Capital allocation
The Board’s aim is to continue to strike a balance between the interests of the business, financial creditors and
the Company’s shareholders. The Company’s capital allocation priorities include investing in the business and
pipeline, maintaining a strong, investment-grade credit rating, potential value-enhancing business development
opportunities, and supporting the progressive dividend policy.
In approving the declaration of dividends, the Board considers both the liquidity of the company and the level of
reserves legally available for distribution. Dividends are paid to shareholders from AstraZeneca PLC, a Group
holding company with no direct operations. The ability of AstraZeneca PLC to make shareholder distributions
is dependent on the creation of profits for distribution and the receipt of funds from subsidiary companies. The
consolidated Group reserves set out in the Condensed consolidated statement of financial position do not reflect
the profit available for distribution to the shareholders of AstraZeneca PLC.
Summarised financial information for guarantee of securities of subsidiaries
AstraZeneca Finance LLC ("AstraZeneca Finance") is the issuer of 0.700% Notes due 2024, 1.200% Notes due
2026, 1.750% Notes due 2028 and 2.250% Notes due 2031 (the "AstraZeneca Finance Notes"). Each series of
AstraZeneca Finance Notes has been fully and unconditionally guaranteed by AstraZeneca PLC. AstraZeneca
Finance is 100% owned by AstraZeneca PLC and each of the guarantees by AstraZeneca PLC is full and
unconditional and joint and several.
The AstraZeneca Finance Notes are senior unsecured obligations of AstraZeneca Finance and rank equally
with all of AstraZeneca Finance’s existing and future senior unsecured and unsubordinated indebtedness. The
guarantee by AstraZeneca PLC of the AstraZeneca Finance Notes is the senior unsecured obligation of
AstraZeneca PLC and ranks equally with all of AstraZeneca PLC’s existing and future senior unsecured and
unsubordinated indebtedness. Each guarantee by AstraZeneca PLC is effectively subordinated to any secured
indebtedness of AstraZeneca PLC to the extent of the value of the assets securing such indebtedness. The
AstraZeneca Finance Notes are structurally subordinated to indebtedness and other liabilities of the subsidiaries
of AstraZeneca PLC, none of which guarantee the AstraZeneca Finance Notes.
AstraZeneca PLC manages substantially all of its operations through divisions, branches and/or investments in
subsidiaries and affiliates. Accordingly, the ability of AstraZeneca PLC to service its debt and guarantee
obligations is also dependent upon the earnings of its subsidiaries, affiliates, branches and divisions, whether
by dividends, distributions, loans or otherwise.
Please refer to the consolidated financial statements of AstraZeneca PLC in our Annual Report on Form 20-F
and reports on Form 6-K with our quarterly financial results as filed or furnished with the SEC for further financial
information regarding AstraZeneca PLC and its consolidated subsidiaries. For further details, terms and
conditions of the AstraZeneca Finance Notes please refer to AstraZeneca PLC’s Form 6-K furnished to the SEC
on 28 May 2021.
28
Total Revenue Financial Performance Sustainability Interim Financial Statements Research and Development
Pursuant to Rule 13-01 and Rule 3-10 of Regulation S-X under the Securities Act of 1933, as amended (the
"Securities Act"), we present below the summary financial information for AstraZeneca PLC, as Guarantor,
excluding its consolidated subsidiaries, and AstraZeneca Finance, as the issuer, excluding its consolidated
subsidiaries. The following summary financial information of AstraZeneca PLC and AstraZeneca Finance is
presented on a combined basis and transactions between the combining entities have been eliminated.
Financial information for non-guarantor entities has been excluded. Intercompany balances and transactions
between the obligor group and the non-obligor subsidiaries are presented on separate lines.
Table 16: Obligor group summarised Statement of comprehensive income
H1 2022 H1 2021
$m $m
Total revenue – –
Gross profit – –
Operating loss (2) (43)
Loss for the period (275) (336)
Transactions with subsidiaries that are not issuers or guarantors 331 2,582
Table 17: Obligor group summarised Statement of financial position information
At 30 Jun 2022 At 30 Jun 2021
$m $m
Current assets 7 7
Non-current assets – 4
Current liabilities (1,838) (2,341)
Non-current liabilities (23,994) (23,808)
Amounts due from subsidiaries that are not issuers or guarantors 7,459 15,039
Amounts due to subsidiaries that are not issuers or guarantors (295) (295)
Foreign exchange
The Company’s transactional currency exposures on working-capital balances, which typically extend for up to
three months, are hedged where practicable using forward foreign-exchange contracts against the individual
companies’ reporting currency. Foreign-exchange gains and losses on forward contracts for transactional
hedging are taken to profit or loss. In addition, the Company’s external dividend payments, paid principally in
pounds sterling and Swedish krona, are fully hedged from announcement to payment date.
Table 18: Currency sensitivities
The Company provides the following currency-sensitivity information:
Exchange
rates versus USD
Annual impact of 5%
strengthening in exchange
rate versus USD ($m)69
Currency Primary Relevance FY 202170 30 Jun
202271 % Change Total
Revenue
Core
Operating
Profit
CNY Total Revenue 6.43 6.70 (4) 277 158
EUR Total Revenue 0.85 0.96 (12) 317 160
JPY Total Revenue 109.83 136.34 (19) 229 158
Other72 420 196
GBP Operating Expense 0.73 0.82 (12) 61 (93)
SEK Operating Expense 8.58 10.26 (16) 6 (82)
69 Based on best prevailing assumptions around currency profiles.
70 Based on average daily spot rates in FY 2021.
71 Spot rates on 30 June 2022.
72 Other currencies include AUD, BRL, CAD, KRW and RUB.
29
Total Revenue Financial Performance Sustainability Interim Financial Statements Research and Development
Sustainability
Since the last quarterly report, AstraZeneca:
Access to healthcare
‒ Expanded the Healthy Heart Africa programme into Rwanda in collaboration with the Rwanda Ministry of
Health and PATH, the programme implementing partner
‒ Launched a collaboration with the Kenya Ministry of Health and Amref Health Africa to deploy mobile clinics
to bring COVID-19 vaccines and non-communicable disease awareness to hard-to-reach communities
across Kenya
‒ Joined EDISON Alliance’s One Billion Lives Challenge, to improve access to innovative and scalable digital
health solutions by 2025. As part of the Challenge, AstraZeneca aims to screen five million patients for lung
cancer using AI-based technology, in collaboration with Qure.ai
‒ Expanded its in-depth health system research as part of the Partnership for Health System Resilience and
Sustainability into 13 new countries (now 21 in total), with Japan and Greece being the first Phase 2 countries
to announce their research results
‒ Announced findings from Young Health Programme-funded research by RTI International that shows for
every $1 invested in evidence-based interventions to prevent and treat mental health issues among
adolescents, $24 in health and economic benefits would be returned to the global economy over 80 years
‒ Also, analysis from health analytics firm Airfinity showed that the AstraZeneca COVID-19 Vaccine helped
save over six million lives during the period 8 December 2020 to 8 December 2021
Environmental protection
‒ Continued to progress conversion of its fleet to electric/hybrid vehicles, currently at 59%
‒ Confirmed collaboration with the WHO-led Alliance for Transformative Action of Climate and Health, to share
recommendations with governments on how to deliver low-carbon, climate resilient healthcare
‒ Wrote, together with SMI73 Health Systems Taskforce, an editorial calling for the healthcare sector to
consider what it can contribute to decarbonisation
‒ Reinforced its commitment to reforestation through tree planting at sites around the world, including Algeria,
Canada, Ghana, Greece, India, Libya and the US
‒ Also, the ground source heat pump at AstraZeneca’s Discovery Centre in Cambridge, one of the largest in
the UK, became the first of its kind to be independently certified as a source of renewable heat by the UK
Government
Ethics and transparency
‒ Contributed to a study by the Tufts Center for the Study of Drug Development on clinical trial diversity
‒ Revised sustainability standards in the Company’s Expectations of Third Parties
‒ Celebrated Pride Month with activities across the world focused on allyship and education to promote
progression towards LGBTQIA+ rights and equality
‒ Was recognised by Diversity Inc in the ‘Top 50 Companies for Diversity’ list, for the third successive year
‒ Was recognised as a 2022 Gold Top Global for Supplier Diversity & Inclusion Champion by WEConnect
International
‒ Was awarded the EcoVadis Silver Medal for the second time, in recognition of the quality of the company’s
sustainability management system
73 Sustainable Markets Initiative.
30
Research and Development Interim Financial Statements Total Revenue Financial Performance Sustainability
Research and development
This section covers R&D events and milestones that have occurred since the prior results announcement.
A comprehensive view of AstraZeneca’s pipeline of medicines in human trials can be found in the latest clinical
trials appendix, available on www.astrazeneca.com/investor-relations. The clinical trials appendix includes
tables with details of the ongoing clinical trials for AstraZeneca medicines and new molecular entities in the
pipeline.
Oncology
AstraZeneca presented new data across its diverse portfolio of cancer medicines at the ASCO (Free ASCO Whitepaper)74 Annual
Meeting, underscoring its ambition to redefine cancer care. More than 100 abstracts featured 18 approved and
potential new medicines across the Company’s industry-leading oncology portfolio, including one plenary
presentation and nine oral presentations.
Significant new trials in Oncology initiated during the period included ADAURA2, a Phase III trial of Tagrisso in
Stage IA2 to IA3 NSCLC after complete resection, TROPION-Breast02, a Phase III trial of datopotamab
deruxtecan in patients with previously untreated locally recurrent inoperable or metastatic TNBC not eligible to
receive PD-1
75/PD-L176 inhibitor therapy; and CAPItello-280, a Phase III trial of capivasertib in combination with
docetaxel in participants with metastatic castrate-resistant prostate cancer.
Imfinzi
During the period, the Company received US regulatory submission acceptance with Priority Review for Imfinzi
in combination with chemotherapy for the treatment of locally advanced or metastatic biliary tract cancer. The
regulatory submission was based on positive results from the TOPAZ-1 Phase III trial. The PDUFA77 date78 is
anticipated to be during the third quarter of 2022.
In June 2022, positive high-level results from a planned interim analysis of the AEGEAN Phase III trial showed
treatment with AstraZeneca’s Imfinzi in combination with neoadjuvant chemotherapy before surgery
demonstrated a statistically significant and meaningful improvement in pathologic complete response compared
to neoadjuvant chemotherapy alone for patients with resectable NSCLC. A statistically significant improvement
in major pathologic response was also observed. The trial will continue as planned to assess the additional
primary endpoint of event-free survival to which the Company, investigators and participants remain blinded.
In July 2022, Imfinzi was assigned category 1 status in the US NCCN79 guidelines for the 1st-line treatment of
patients with biliary tract cancer, based on the results from the TOPAZ-1 Phase III trial.
Lynparza
During the period, AstraZeneca and MSD’s Lynparza was recommended for marketing authorisation in the EU
as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with
germline BRCA1/2 mutations who have HER2-negative high-risk early breast cancer previously treated with
neoadjuvant or adjuvant chemotherapy, by the Committee for CHMP of the EMA, based on the results of the
OlympiA Phase III trial.
In July 2022, AstraZeneca and MSD received notification from an Independent Data Monitoring Committee that
data from a pre-specified interim efficacy analysis of the LYNK-003 Phase III trial of Lynparza in patients with
unresectable or metastatic colorectal cancer was unlikely to demonstrate a benefit to patients and
recommended that the trial be discontinued. Accordingly, MSD announced that the trial would stop for futility.
74 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper).
75 Programmed cell death protein 1.
76 Programmed death-ligand 1.
77 Prescription Drug User Fee Act.
78 The PDFUA date is the day the US FDA targets for regulatory decision.
79 National Comprehensive Cancer Network.
31
Research and Development Interim Financial Statements Total Revenue Financial Performance Sustainability
Calquence
In June 2022, at the aforementioned ASCO (Free ASCO Whitepaper) Annual Meeting, updated results from the ELEVATE-TN Phase III
trial showed Calquence maintained a statistically significant PFS80 benefit versus chlorambucil plus
obinutuzumab and a safety and tolerability profile consistent with the known profile for Calquence at a median
follow up of approximately five years in combination and as a monotherapy in CLL. Results also showed longer
OS81 for Calquence combined with obinutuzumab compared with chlorambucil combined with obinutuzumab in
previously untreated adults with CLL.
Separately, follow-up data from the ASCEND Phase III trial showed Calquence demonstrated a sustained PFS
benefit at four years based on investigator assessment compared with investigator’s choice of rituximab
combined with either idelalisib or bendamustine in adults with relapsed or refractory CLL.
Enhertu
In May 2022, AstraZeneca and Daiichi Sankyo’s Enhertu was approved in the US for the treatment of patients
with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based
regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease
recurrence during or within six months of completing therapy. The approval by the US FDA82 was based on
positive results from the DESTINY-Breast03 Phase III trial.
In July 2022, Enhertu was approved for use in the EU as a monotherapy for the treatment of adult patients with
unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based
regimens. The approval followed the EMA’s positive CHMP opinion based on the results from DESTINYBreast03 Phase III trial.
At this year’s ASCO (Free ASCO Whitepaper) Annual Meeting, results from the DESTINY-Breast04 Phase III trial were presented during
the Plenary Session. Enhertu demonstrated superior and clinically meaningful PFS and OS in previously treated
patients with HER2-low unresectable and/or metastatic breast cancer with HR-positive or HR-negative disease
versus standard of care physician’s choice of chemotherapy. Results were simultaneously published in The
New England Journal of Medicine.
Soon after the presentation of these data, Enhertu was assigned category 1 status in the US NCCN guidelines
for the treatment of patients with (HR-positive and HR-negative) tumours that are HER2-low, who have received
at least one prior line of chemotherapy for metastatic disease and, where the tumour is HR-positive, are
refractory to endocrine therapy. In July, ASCO (Free ASCO Whitepaper) guidelines were updated to recommend Enhertu in the same
setting.
During the period, based on the results of the DESTINY-Breast04 Phase III trial, AstraZeneca and Daiichi
Sankyo received US regulatory submission acceptance with Priority Review, EU regulatory submission
acceptance, and completed regulatory submission in Japan.
Camizestrant
During the period, the US FDA granted Fast Track Designation to camizestrant in combination with palbociclib
or abemaciclib in the treatment of in patients with HR-positive/HER2-negative metastatic breast cancer with
detectable ESR183 mutations who have not experienced disease progression on first-line therapy (SERENA-6).
80 Progression free survival.
81 Overall survival.
82 US Food and Drug Agency
83 Oestrogen Receptor 1 gene.
32
Research and Development Interim Financial Statements Total Revenue Financial Performance Sustainability
BioPharmaceuticals – CVRM
Brilinta
During the period, AstraZeneca withdrew Brilinta’s regulatory submission in China to prevent acute ischaemic
stroke or TIA84. The submission was based on the THALES Phase III trial where Brilinta plus aspirin significantly
reduced the rate of stroke and death compared to aspirin alone in patients with acute ischaemic stroke or TIA.
Brilinta was approved in the US in the aforementioned indication in November 2020.
Farxiga
In May 2022, the Company announced positive high-level results from the DELIVER Phase III trial where
Farxiga showed a statistically significant and clinically meaningful reduction in the primary endpoint of
cardiovascular death or worsening heart failure. The trial was conducted in patients with heart failure with mildly
reduced or preserved ejection fraction, defined as left ventricular ejection fraction greater than 40%.
Bydureon
During the period, AstraZeneca received a marketing extension in the EU for Bydureon BCise to include the
treatment of type-2 diabetes in children and adolescents aged 10 years and above.
Eplontersen
In June 2022, AstraZeneca and Ionis Pharmaceuticals, Inc. announced positive high-level results from the
NEURO-TTRansform Phase III trial for eplontersen in patients with hereditary transthyretin-mediated amyloid
polyneuropathy. In the trial, eplontersen reached a statistically significant and clinically meaningful change from
baseline for its co-primary endpoint of percent change in serum TTR85 concentration, reducing TTR protein
production. Eplontersen also reached its co-primary endpoint of change from baseline in the modified
Neuropathy Impairment Score +7, a measure of neuropathic disease progression, versus the external placebo
group. The secondary endpoint of change from baseline in the Norfolk Quality of Life Questionnaire-Diabetic
Neuropathy was also met, showing that treatment with eplontersen significantly improved patient-reported
quality of life versus the external placebo group.
84 Transient ischaemic attack of stroke.
85 Transthyretin.
33
Research and Development Interim Financial Statements Total Revenue Financial Performance Sustainability
BioPharmaceuticals – R&I
During the period the Company initiated IRIS, a Phase III trial of Saphnelo in lupus nephritis.
Tezspire
In July 2022, Tezspire was recommended for approval in the EU by the CHMP for the treatment of severe
asthma. Tezspire is the first and only biologic approved in a broad population of severe asthma irrespective of
biomarker status.
The GINA86 severe asthma guidelines were updated during the period, to include anti-TSLP, as an add-on
biologic therapy for patients 12 years and over with severe asthma.
PT027
In May 2022, full results from the Phase III MANDALA trial were published in The New England Journal of
Medicine and presented along with results from the Phase III DENALI trial at the American Thoracic Society
International Conference. The use of PT027, a novel fixed-dose combination of albuterol and budesonide, as
an as-needed rescue medicine significantly reduced the risk of severe exacerbation by 27% in patients with
asthma, compared with albuterol alone.
BioPharmaceuticals – V&I
Evusheld
Detailed results published in The Lancet Respiratory Medicine from the Phase III TACKLE outpatient treatment
trial showed that Evusheld provided clinically and statistically significant protection against progression to
severe COVID-19 or death from any cause compared to placebo, with treatment with Evusheld earlier in the
disease course leading to more favourable outcomes.
A single 600mg intramuscular dose of Evusheld significantly reduced the relative risk of progressing to severe
COVID-19 or death (from any cause) by 50% through Day 29 compared to placebo in non-hospitalised patients
with mild-to-moderate COVID-19 who were symptomatic for seven days or less, the trial’s primary endpoint. In
pre-specified analyses of participants who received treatment within three days of symptom onset, Evusheld
reduced the risk of developing severe COVID-19 or death (from any cause) by 88% compared to placebo, and
the risk reduction was 67% when participants received Evusheld within five days of symptom onset.
Preclinical pseudovirus assay data from the University of Oxford, published in Cell, demonstrated that Evusheld
retains neutralisation activity against the Omicron BA.4 and BA.5 variants.
Nirsevimab
Results from a pre-specified pooled analysis of the pivotal Phase III/IIb MELODY trial presented at the European
Society for Paediatric Infectious Diseases meeting showed that nirsevimab demonstrated efficacy (relative risk
reduction versus placebo) of 79.5% against medically-attended LRTI87, such as bronchiolitis or pneumonia,
caused by RSV in infants born at term or preterm entering their first RSV season. The pooled analysis evaluated
healthy preterm and term infants who received the optimised dose of nirsevimab compared to placebo through
Day 151 and showed efficacy of 77.3% against RSV LRTI hospitalisations.
Vaxzevria
In May 2022, Vaxzevria was granted EMA approval for use in the EU as a third dose booster in adults.
Airfinity, the provider of global real-time health intelligence, has analysed data from Imperial College, London,
and estimates that Vaxzevria saved over six million lives during the period 8 December 2020 to 8 December
2021. The data from Imperial College was published in The Lancet in June 2022.
Vaxzevria was found to be 73% effective at preventing Omicron-related infections after a fourth dose in a realworld evidence study by Chiang Mai University in Thailand.
86 Global Initiative for Asthma.
87 Lower respiratory tract infection.
34
Research and Development Interim Financial Statements Total Revenue Financial Performance Sustainability
Rare Disease
Ultomiris
In May 2022, the Company announced results of the CHAMPION-NMOSD Phase III trial demonstrating
Ultomiris achieved a statistically significant and clinically meaningful reduction in the risk of relapse in adults
with anti-aquaporin-4 antibody-positive NMOSD compared to the external placebo arm. Ultomiris met primary
endpoint of time to first on-trial relapse and as confirmed by an independent adjudication committee; notably,
zero adjudicated relapses were observed over a median treatment duration of 73 weeks.
Ultomiris also received regulatory submission acceptance in China for the treatment of gMG, as well as positive
CHMP opinion in the EU as an add-on to standard therapy for the treatment of adult patients with gMG. The
regulatory submission were based on positive results from the CHAMPION-MG Phase III trial. Additionally,
Ultomiris subcutaneous formulation received regulatory approval in the US for the treatment of PNH and aHUS.
Koselugo
Koselugo was granted Priority Review in China for the treatment of NF1-PN in children 2 years old or over.
ALXN1840
In June 2022, Results from the FoCus Phase III trial in Wilson disease were presented at the 2022 International
Liver Congress. The detailed results showed ALXN1840, a novel once-daily oral medicine, met its primary
endpoint, demonstrating three-times greater copper mobilisation from tissues compared to standard of care,
including in patients who had been treated previously for an average of 10 years. Patients taking ALXN1840
experienced rapid copper mobilisation, with a response at four weeks and sustained through 48 weeks.
35
Total Revenue Financial Performance Sustainability Research and Development Interim Financial Statements
Interim financial statements
Table 19: Condensed consolidated statement of comprehensive income – H1 2022
For the half year ended 30 June 2022 2021
$m $m
Total Revenue 22,161 15,540
Product Sales 21,610 15,302
Collaboration Revenue 551 238
Cost of Sales (6,509) (4,055)
Gross profit 15,652 11,485
Distribution expense (254) (202)
Research and development expense (4,679) (3,542)
Selling, general and administrative expense (9,521) (6,027)
Other operating income and expense 219 1,308
Operating profit 1,417 3,022
Finance income 35 27
Finance expense (647) (629)
Share of after tax losses in associates and joint ventures (5) (48)
Profit before tax 800 2,372
Taxation (52) (260)
Profit for the period 748 2,112
Other comprehensive (loss)/income
Items that will not be reclassified to profit or loss
Remeasurement of the defined benefit pension liability 1,031 692
Net losses on equity investments measured at fair value through other
comprehensive income (12) (27)
Fair value movements related to own credit risk on bonds designated as fair value
through profit or loss 2 2
Tax on items that will not be reclassified to profit or loss (275) 52
746 719
Items that may be reclassified subsequently to profit or loss
Foreign exchange arising on consolidation (1,326) 59
Foreign exchange arising on designated borrowings in net investment hedges (195) (230)
Fair value movements on cash flow hedges (138) (59)
Fair value movements on cash flow hedges transferred to profit or loss 131 73
Fair value movements on derivatives designated in net investment hedges 34 7
Costs of hedging (13) (2)
Tax on items that may be reclassified subsequently to profit or loss 46 18
(1,461) (134)
Other comprehensive (loss)/income, net of tax (715) 585
Total comprehensive income for the period 33 2,697
Profit attributable to:
Owners of the Parent 746 2,111
Non-controlling interests 2 1
748 2,112
Total comprehensive income attributable to:
Owners of the Parent 33 2,696
Non-controlling interests – 1
33 2,697
Basic earnings per $0.25 Ordinary Share $0.48 $1.61
Diluted earnings per $0.25 Ordinary Share $0.48 $1.60
Weighted average number of Ordinary Shares in issue (m) 1,548 1,312
Diluted weighted average number of Ordinary Shares in issue (m) 1,561 1,319
36
Total Revenue Financial Performance Sustainability Research and Development Interim Financial Statements
Table 20: Condensed consolidated statement of comprehensive income – Q2 2022
For the quarter ended 30 June Unreviewed88
2022
Unreviewed
2021
$m $m
Total Revenue 10,771 8,220
Product Sales 10,630 8,045
Collaboration Revenue 141 175
Cost of Sales (2,998) (2,191)
Gross profit 7,773 6,029
Distribution expense (129) (103)
Research and development expense (2,546) (1,829)
Selling, general and administrative expense (4,681) (3,098)
Other operating income and expense 122 128
Operating profit 539 1,127
Finance income 18 7
Finance expense (311) (326)
Share of after tax losses in associates and joint ventures 1 (44)
Profit before tax 247 764
Taxation 113 (214)
Profit for the period 360 550
Other comprehensive (loss)/income
Items that will not be reclassified to profit or loss
Remeasurement of the defined benefit pension liability 696 211
Net (losses)/gains on equity investments measured at fair value through other
comprehensive income (30) 81
Fair value movements related to own credit risk on bonds designated as fair value
through profit or loss 2 1
Tax on items that will not be reclassified to profit or loss (181) 146
487 439
Items that may be reclassified subsequently to profit or loss
Foreign exchange arising on consolidation (1,107) 166
Foreign exchange arising on designated borrowings in net investment hedges (163) 72
Fair value movements on cash flow hedges (143) 27
Fair value movements on cash flow hedges transferred to profit or loss 120 (48)
Fair value movements on derivatives designated in net investment hedges 42 (6)
Costs of hedging (13) (1)
Tax on items that may be reclassified subsequently to profit or loss 45 (8)
(1,219) 202
Other comprehensive (loss)/income, net of tax (732) 641
Total comprehensive (loss)/income for the period (372) 1,191
Profit attributable to:
Owners of the Parent 360 550
Non-controlling interests – –
360 550
Total comprehensive (loss)/income attributable to:
Owners of the Parent (372) 1,190
Non-controlling interests – 1
(372) 1,191
Basic earnings per $0.25 Ordinary Share $0.23 $0.42
Diluted earnings per $0.25 Ordinary Share $0.23 $0.42
Weighted average number of Ordinary Shares in issue (m) 1,549 1,312
Diluted weighted average number of Ordinary Shares in issue (m) 1,560 1,318
88
The Q2 2022 and Q2 2021 information in respect of the three months ended 30 June 2022 and 30 June 2021 respectively included in
the Interim financial statements has not been reviewed by PricewaterhouseCoopers LLP.
37
Total Revenue Financial Performance Sustainability Research and Development Interim Financial Statements
Table 21: Condensed consolidated statement of financial position
Reviewed89 Audited Reviewed
At 30 Jun
2022
At 31 Dec
2021
At 30 Jun
2021
$m $m $m
Assets
Non-current assets
Property, plant and equipment 8,722 9,183 8,357
Right-of-use assets 905 988 674
Goodwill 19,821 19,997 11,798
Intangible assets 39,900 42,387 20,006
Investments in associates and joint ventures 56 69 48
Other investments 1,124 1,168 1,072
Derivative financial instruments 113 102 124
Other receivables 881 895 565
Deferred tax assets 4,140 4,330 3,723
75,662 79,119 46,367
Current assets
Inventories 6,220 8,983 4,762
Trade and other receivables 8,908 9,644 6,356
Other investments 70 69 62
Derivative financial instruments 109 83 41
Intangible assets 89 105 –
Income tax receivable 704 663 486
Cash and cash equivalents 4,817 6,329 15,567
Assets held for sale – 368 –
20,917 26,244 27,274
Total assets 96,579 105,363 73,641
Liabilities
Current liabilities
Interest-bearing loans and borrowings (2,162) (1,660) (2,696)
Lease liabilities (220) (233) (198)
Trade and other payables (17,821) (18,938) (17,729)
Derivative financial instruments (90) (79) (17)
Provisions (541) (768) (802)
Income tax payable (981) (916) (780)
(21,815) (22,594) (22,222)
Non-current liabilities
Interest-bearing loans and borrowings (26,461) (28,134) (24,109)
Lease liabilities (685) (754) (492)
Derivative financial instruments (180) (45) (3)
Deferred tax liabilities (5,275) (6,206) (2,927)
Retirement benefit obligations (1,310) (2,454) (2,383)
Provisions (892) (956) (620)
Other payables (4,010) (4,933) (5,192)
(38,813) (43,482) (35,726)
Total liabilities (60,628) (66,076) (57,948)
Net assets 35,951 39,287 15,693
Equity
Capital and reserves attributable to equity holders of the Parent
Share capital 387 387 328
Share premium account 35,134 35,126 7,980
Other reserves 2,068 2,045 2,033
Retained earnings (1,657) 1,710 5,335
35,932 39,268 15,676
89 The Condensed consolidated statement of financial position as at 30 June 2022 and 30 June 2021 has been reviewed by
PricewaterhouseCoopers LLP. The Condensed consolidated statement of financial position as at 31 December 2021 has been audited
by PricewaterhouseCoopers LLP.
38
Total Revenue Financial Performance Sustainability Research and Development Interim Financial Statements
Reviewed89 Audited Reviewed
At 30 Jun
2022
At 31 Dec
2021
At 30 Jun
2021
$m $m $m
Non-controlling interests 19 19 17
Total equity 35,951 39,287 15,693
Table 22: Condensed consolidated statement of changes in equity
Share
capital
Share
premium
account
Other
reserves
Retained
earnings
Total
attributable
to ownersof
the parent
Noncontrolling
interests
Total
equity
$m $m $m $m $m $m $m
At 1 Jan 2021 328 7,971 2,024 5,299 15,622 16 15,638
Profit for the period – – – 2,111 2,111 1 2,112
Other comprehensive income – – – 585 585 – 585
Transfer to other reserves – – 9 (9) – – –
Transactions with owners:
Dividends – – – (2,490) (2,490) – (2,490)
Issue of Ordinary Shares – 9 – – 9 – 9
Share-based payments charge
for the period – – – 160 160 – 160
Settlement of share plan
awards – – – (321) (321) – (321)
Net movement – 9 9 36 54 1 55
At 30 Jun 2021 328 7,980 2,033 5,335 15,676 17 15,693
At 1 Jan 2022 387 35,126 2,045 1,710 39,268 19 39,287
Profit for the period – – – 746 746 2 748
Other comprehensive loss – – – (713) (713) (2) (715)
Transfer to other reserves – – 23 (23) – – –
Transactions with owners:
Dividends – – – (3,046) (3,046) – (3,046)
Issue of Ordinary Shares – 8 – – 8 – 8
Share-based payments charge
for the period – – – 346 346 – 346
Settlement of share plan awards – – – (677) (677) – (677)
Net movement – 8 23 (3,367) (3,336) – (3,336)
At 30 Jun 2022 387 35,134 2,068 (1,657) 35,932 19 35,951
39
Total Revenue Financial Performance Sustainability Research and Development Interim Financial Statements
Table 23: Condensed consolidated statement of cash flows
For the half year ended 30 June 2022 2021
$m $m
Cash flows from operating activities
Profit before tax 800 2,372
Finance income and expense 612 602
Share of after tax losses of associates and joint ventures
5 48
Depreciation, amortisation and impairment 2,666 1,550
Decrease in working capital and short
-term provisions 2,391 857
Gains on disposal of intangible assets (81) (354)
Gains on disposal of investments in associates and joint ventures
– (776)
Fair value movements on contingent consideration arising from business
combinations 293 82
Non
-cash and other movements (814) (363)
Cash generated from operations 5,872 4,018
Interest paid (386) (323)
Tax paid (1,006) (869)
Net cash inflow from operating activities 4,480 2,826
Cash flows from investing activities
Payments upon vesting of employee share awards attributable to business
combinations (158)
–
Payment of contingent consideration from business combinations (367) (309)
Purchase of property, plant and equipment (472) (508)
Disposal of property, plant and equipment
–
4
Purchase of intangible assets (434) (314)
Disposal of intangible assets and assets held for sale 442 573
Purchase of non
-current asset investments (28) (10)
Disposal of non
-current asset investments 35
–
Movement in short
-term investments, fixed deposits and other investing
instruments
9 135
Payments to associates and joint ventures (5) (55)
Disposal of investments in associates and joint ventures
– 776
Interest received 10 27
Net cash (outflow)/inflow from investing activities (968) 319
Net cash inflow before financing activities 3,512 3,145
Cash flows from financing activities
Proceeds from issue of share capital
8
9
Repayment of loans and borrowings (1,257) (611)
Issue of loans
– 7,944
Dividends paid (2,971) (2,469)
Hedge contracts relating to dividend payments (77) (22)
Repayment of obligations under leases (134) (111)
Movement in short
-term borrowings 316 (182)
Payment of Acerta Pharma share purchase liability (920)
–
Net cash
(outflow)/inflow from financing activities (5,035) 4,5
5
8
Net
(decrease)/increase in cash and cash equivalents in the period (1,523) 7,703
Cash and cash equivalents at the beginning of the period 6,038 7,546
Exchange rate effects (35) (52)
Cash and cash equivalents at the end of the period 4,480 15,197
Cash and cash equivalents consist of:
Cash and cash equivalents 4,817 15,567
Overdrafts (337) (370)
4,480 15,197
40
Total Revenue Financial Performance Sustainability Research and Development Interim Financial Statements
Responsibility statement of the directors in respect of the half-yearly financial report
We confirm that to the best of our knowledge:
‒ the condensed consolidated Interim financial statements have been prepared in accordance with IAS 34
‘Interim Financial Reporting’ as issued by the International Accounting Standards Board (IASB), IAS 34 as
adopted by the European Union and UK-adopted IAS 34;
‒ the half-yearly management report gives a true and fair view of the assets, liabilities, financial position and
profit or loss of the company;
‒ the half-yearly management report includes a fair review of the information required by:
a) DTR 4.2.7R of the Disclosure and Transparency Rules, being an indication of important events that have
occurred during the first six months of the financial year and their impact on the condensed consolidated
Interim financial statements; and a description of the principal risks and uncertainties for the remaining
six months of the year; and
b) DTR 4.2.8R of the Disclosure and Transparency Rules, being related party transactions that have taken
place in the first six months of the current financial year and that have materially affected the financial
position or performance of the enterprise during that period; and any changes in the related party
transactions described in the last annual report that could do so.
The Board
The Board of Directors that served during all or part of the six month period to 30 June 2022 and their respective
responsibilities can be found on the Leadership team section of astrazeneca.com.
Approved by the Board and signed on its behalf by
Pascal Soriot
Chief Executive Officer
29 July 2022
41
Total Revenue Financial Performance Sustainability Research and Development Interim Financial Statements
Independent review report to AstraZeneca PLC
Report on the condensed consolidated interim financial statements
Our conclusion
We have reviewed AstraZeneca PLC’s condensed consolidated interim financial statements (the "Interim
financial statements") in the half-yearly financial report of AstraZeneca PLC for the 6 month period ended 30
June 2022 (the "period").
Based on our review, nothing has come to our attention that causes us to believe that the Interim financial
statements are not prepared, in all material respects, in accordance with International Accounting Standard 34,
‘Interim Financial Reporting’ (IAS 34), as issued by the International Accounting Standards Board (IASB), IAS
34 as adopted by the European Union and UK-adopted IAS 34, and the Disclosure Guidance and Transparency
Rules sourcebook of the United Kingdom’s Financial Conduct Authority.
The Interim financial statements comprise:
‒ the Condensed consolidated statement of comprehensive income for the period then ended – H1 2022;
‒ the Condensed consolidated statement of financial position as at 30 June 2022;
‒ the Condensed consolidated statement of changes in equity for the period then ended;
‒ the Condensed consolidated statement of cash flows for the period then ended; and
‒ the explanatory notes to the Interim financial statements.
The Interim financial statements included in the half-yearly financial report of AstraZeneca PLC have been
prepared in accordance with International Accounting Standard 34, ‘Interim Financial Reporting’ (IAS 34), as
issued by the International Accounting Standards Board (IASB), IAS 34 as adopted by the European Union and
UK-adopted IAS 34, and the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom’s
Financial Conduct Authority.
Basis for conclusion
We conducted our review in accordance with International Standard on Review Engagements (UK) 2410,
‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’ issued by the
Financial Reporting Council for use in the United Kingdom. A review of interim financial information consists of
making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical
and other review procedures.
A review is substantially less in scope than an audit conducted in accordance with International Standards on
Auditing (UK) and, consequently, does not enable us to obtain assurance that we would become aware of all
significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
We have read the other information contained in the half-yearly financial report and considered whether it
contains any apparent misstatements or material inconsistencies with the information in the Interim financial
statements.
Conclusions relating to going concern
Based on our review procedures, which are less extensive than those performed in an audit as described in the
Basis for conclusion section of this report, nothing has come to our attention to suggest that the directors have
inappropriately adopted the going concern basis of accounting or that the directors have identified material
uncertainties relating to going concern that are not appropriately disclosed. This conclusion is based on the
review procedures performed in accordance with this ISRE. However, future events or conditions may cause
the group to cease to continue as a going concern.
42
Total Revenue Financial Performance Sustainability Research and Development Interim Financial Statements
Independent review report to AstraZeneca PLC
Responsibilities for the Interim financial statements and the review
Our responsibilities and those of the directors
The half-yearly financial report, including the Interim financial statements, is the responsibility of, and has been
approved by the directors. The directors are responsible for preparing the half-yearly financial report in
accordance with the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom’s
Financial Conduct Authority. In preparing the half-yearly financial report, including the Interim financial
statements, the directors are responsible for assessing the group’s ability to continue as a going concern,
disclosing, as applicable, matters related to going concern and using the going concern basis of accounting
unless the directors either intend to liquidate the group or to cease operations, or have no realistic alternative
but to do so.
Our responsibility is to express a conclusion on the Interim financial statements in the half-yearly financial report
based on our review. Our conclusion, including our Conclusions relating to going concern, is based on
procedures that are less extensive than audit procedures, as described in the Basis for conclusion paragraph
of this report. This report, including the conclusion, has been prepared for and only for the company for the
purpose of complying with the Disclosure Guidance and Transparency Rules sourcebook of the United
Kingdom’s Financial Conduct Authority and for no other purpose. We do not, in giving this conclusion, accept
or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose
hands it may come save where expressly agreed by our prior consent in writing.
PricewaterhouseCoopers LLP
Chartered Accountants
London
29 July 2022
43
Total Revenue Financial Performance Sustainability Research and Development Interim Financial Statements
Notes to the Interim financial statements
Note 1: Basis of preparation and accounting policies
These unaudited condensed consolidated Interim financial statements for the six months ended 30 June 2022
have been prepared in accordance with International Accounting Standard 34, ‘Interim Financial Reporting’ (IAS
34), as issued by the International Accounting Standards Board (IASB), IAS 34 as adopted by the European
Union, UK-adopted IAS 34 and the Disclosure Guidance and Transparency Rules sourcebook of the United
Kingdom’s Financial Conduct Authority and with the requirements of the Companies Act 2006 as applicable to
companies reporting under those standards.
The unaudited Interim financial statements for the six months ended 30 June 2022 include Alexion’s results for
the period. Alexion was consolidated into the Group’s results from 21 July 2021, hence Alexion’s results are not
included in the comparative periods shown.
The unaudited Interim financial statements for the six months ended 30 June 2022 were approved by the Board
of Directors for publication on 29 July 2022.
This results announcement does not constitute statutory accounts of the Group within the meaning of sections
434(3) and 435(3) of the Companies Act 2006. The annual financial statements of the Group for the year ended
31 December 2021 were prepared in accordance with UK-adopted International Accounting Standards and with
the requirements of the Companies Act 2006. The annual financial statements also comply fully with IFRSs as
issued by the IASB and International Accounting Standards as adopted by the European Union. Except for the
estimation of the interim income tax charge, the Interim financial statements have been prepared applying the
accounting policies that were applied in the preparation of the Group’s published consolidated financial
statements for the year ended 31 December 2021.
The comparative figures for the financial year ended 31 December 2021 are not the Group’s statutory accounts
for that financial year. Those accounts have been reported on by the Group’s auditors and have been delivered
to the registrar of companies; their report was (i) unqualified, (ii) did not include a reference to any matters to
which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a
statement under section 498(2) or (3) of the Companies Act 2006.
Global and/or geopolitical events
There were no material accounting impacts identified relating to COVID-19 during the six months ended 30
June 2022.
The Group’s current focus is to continue compliant business operations in Russia and Ukraine, focussing on
safeguarding our employees, ensuring continuity of supply of essential and life-saving medicines and
contributing to humanitarian relief efforts. There are no material accounting impacts arising from the conflict
impacting our H1 2022 reporting. The situation is dynamic and any future impact on our business is uncertain.
Throughout July 2022, a range of EU/US/Swiss and UK sanctions have come into force placing restrictions on
specific business activities and/or individuals related to on-going business with Russia. We are monitoring
closely and our work in this regard continues to progress to provide assurance over managements activities to
ensure ongoing sanctions compliance.
The Group will continue to monitor these areas of increased judgement, estimation and risk for material
changes.
Going concern
The Group has considerable financial resources available. As at 30 June 2022, the Group had $9.7bn in
financial resources (cash and cash-equivalent balances of $4.8bn and undrawn committed bank facilities of
$4.9bn available until April 2025, with only $2.4bn of borrowings due within one year). All facilities contain no
financial covenants and were undrawn at 30 June 2022.
The Group’s revenues are largely derived from sales of medicines covered by patents which provide a relatively
high level of resilience and predictability to cash inflows, although government price interventions in response
to budgetary constraints are expected to continue to affect adversely revenues in some of our significant
markets. The Group, however, anticipates new revenue streams from both recently launched medicines and
44
Total Revenue Financial Performance Sustainability Research and Development Interim Financial Statements
those in development, and the Group has a wide diversity of customers and suppliers across different
geographic areas.
Consequently, the Directors believe that, overall, the Group is well-placed to manage its business risks
successfully.
Accordingly, the going concern basis has been adopted in these Interim financial statements.
Legal proceedings
The information contained in Note 6 updates the disclosures concerning legal proceedings and contingent
liabilities in the Group’s Annual Report and Form 20-F Information 2021.
Note 2: Intangible assets
In accordance with IAS 36 ‘Impairment of Assets’, reviews for triggers of impairment or impairment reversals at
an individual asset or cash-generating-unit level were conducted, and impairment tests carried out where
triggers were identified. As a result, total net impairment reversals of $26m have been recorded against
intangible assets during the six months ended 30 June 2022 (H1 2021: $55m charge). Net impairment reversals
in respect of medicines in development and launched medicines were $9m (H1 2021: $nil) and $nil (H1 2021:
$55m charge) respectively.
Note 3: Net Debt
The table below provides an analysis of Net Debt and a reconciliation of Net Cash Flow to the movement in Net
Debt. The Group monitors Net Debt as part of its capital-management policy as described in Note 28 of the
Annual Report and Form 20-F Information 2021. Net Debt is a non-GAAP financial measure.
Table 24: Net Debt
At 1 Jan
2022 Cash flow Non-cash
& other
Exchange
movements
At 30 Jun
2022
$m $m $m $m $m
Non-current instalments of loans (28,134) – 1,409 264 (26,461)
Non-current instalments of leases (754) – 37 32 (685)
Total long-term debt (28,888) – 1,446 296 (27,146)
Current instalments of loans (1,273) 1,257 (1,399) – (1,415)
Current instalments of leases (233) 133 (131) 11 (220)
Commercial paper – (256) – – (256)
Bank collateral (93) (18) – – (111)
Other short-term borrowings excluding overdrafts (3) (42) – 2 (43)
Overdrafts (291) (65) – 19 (337)
Total current debt (1,893) 1,009 (1,530) 32 (2,382)
Gross borrowings (30,781) 1,009 (84) 328 (29,528)
Net derivative financial instruments 61 66 (175) – (48)
Net borrowings (30,720) 1,075 (259) 328 (29,576)
Cash and cash equivalents 6,329 (1,458) – (54) 4,817
Other investments – current 69 2 – (1) 70
Cash and investments 6,398 (1,456) – (55) 4,887
Net Debt (24,322) (381) (259) 273 (24,689)
Non-cash movements in the period include fair-value adjustments under IFRS 9.
The Group has agreements with some bank counterparties whereby the parties agree to post cash collateral
on financial derivatives, for the benefit of the other, equivalent to the market valuation of the derivative positions
above a predetermined threshold. The carrying value of such cash collateral held by the Group at 30 June 2022
was $111m (31 December 2021: $93m) and the carrying value of such cash collateral posted by the Group at
30 June 2022 was $184m (31 December 2021: $47m). Cash collateral posted by the Group is presented within
Cash and cash equivalents.
45
Total Revenue Financial Performance Sustainability Research and Development Interim Financial Statements
Restricted cash and cash equivalents at 30 June 2022 totalled $236m (31 December 2021: $47m), comprising
cash collateral posted by the Group and other items.
The equivalent GAAP measure to Net Debt is ‘liabilities arising from financing activities’, which excludes the
amounts for cash and overdrafts, other investments and non-financing derivatives shown above and includes
the Acerta Pharma share purchase liability of $1,590m (31 December 2021: $2,458m), $838m of which is shown
in current other payables and $752m is shown in non-current other payables.
Net Debt increased by $367m in the year to date to $24,689m. Details of the committed undrawn bank facilities
are disclosed within the going concern section of Note 1.
During the six months to 30 June 2022, there were no changes to the Company’s solicited credit ratings issued
by Standard and Poor’s (long term: A-; short term: A-2) and from Moody’s (long term: A3; short term: P-2).
Note 4: Financial Instruments
As detailed in the Group’s most recent annual financial statements, the principal financial instruments consist
of derivative financial instruments, other investments, trade and other receivables, cash and cash equivalents,
trade and other payables, lease liabilities and interest-bearing loans and borrowings.
The Group has certain equity investments held at $180m at 30 June 2022 (31 December 2021: $104m) that are
categorised as Level 3 in the fair-value hierarchy and for which fair-value gains of $48m (FY 2021: $nil) have
been recognised in the six months ended 30 June 2022. In the absence of specific market data, these
unlisted investments are held at fair value based on the cost of investment and adjusting as necessary for
impairments and revaluations on new funding rounds, which are seen to approximate the fair value. All other
fair-value gains and/or losses that are presented in Net losses on equity investments measured at fair value
through other comprehensive income in the Condensed consolidated statement of comprehensive income for
the six months ended 30 June 2022 are Level 1 fair-value measurements, valued based on quoted prices in
active markets.
Financial instruments measured at fair value include $1,194m of other investments, $3,098m held in moneymarket funds, $301m of loans designated at fair value through profit or loss and $48m of derivatives as at 30
June 2022. With the exception of derivatives being Level 2 fair-valued, the aforementioned balances are Level
1 fair-valued. The total fair value of interest-bearing loans and borrowings at 30 June 2022, which have a
carrying value of $29,528m in the Condensed consolidated statement of financial position, was $29,019m.
Table 25: Financial instruments – contingent consideration
2022 2021
Diabetes
alliance Other Total Total
$m $m $m $m
At 1 January 2,544 321 2,865 3,323
Settlements (358) (9) (367) (309)
Disposals – (121) (121) –
Revaluations 320 (27) 293 82
Discount unwind 81 4 85 112
At 30 June 2,587 168 2,755 3,208
Contingent consideration arising from business combinations is fair-valued using decision-tree analysis, with
key inputs including the probability of success, consideration of potential delays and the expected levels of
future revenues.
The contingent consideration balance relating to BMS’s share of the global diabetes alliance of $2,587m
(31 December 2021: $2,544m) would increase/decrease by $259m with an increase/decline in sales of 10%,
as compared with the current estimates.
46
Total Revenue Financial Performance Sustainability Research and Development Interim Financial Statements
Note 5: Pensions and other post-retirement benefit obligations
The net pensions and other post-retirement benefit obligations position, as recorded under IAS 19, at 30 June
2022 was a liability of $1,136m (31 December 2021: $2,454m liability). Pension schemes in a net surplus
position at 30 June 2022 totalled $174m (31 December 2021: $nil) and are recorded within Other receivables
in non-current assets. Pension schemes in a net deficit position at 30 June 2022 totalled $1,310m (31 December
2021: $2,454m) and are recorded within Retirement benefit obligations in non-current liabilities.
The decrease in the net liability of $1,318m is driven by actuarial gains of $1,031m that have been reflected
within the Condensed consolidated statement of comprehensive income.
Changes in actuarial assumptions, primarily movements in discount rates, led to a decrease in the net liability
in the half of $2,599m (a decrease in UK, Sweden, US and German liabilities of $1,698m, $518m, $221m and
$162m respectively), which reflected increases in corporate bond yields. These movements were partially offset
by decreases in the pension fund asset values in the half of $1,563m and experience losses of $5m.
Note 6: Legal proceedings and contingent liabilities
AstraZeneca is involved in various legal proceedings considered typical to its business, including litigation and
investigations, including Government investigations, relating to product liability, commercial disputes,
infringement of intellectual property (IP) rights, the validity of certain patents, anti-trust law and sales and
marketing practices. The matters discussed below constitute the more significant developments since
publication of the disclosures concerning legal proceedings in the Company’s Annual Report and Form 20-F
Information 2021 (the Disclosures). Unless noted otherwise below or in the Disclosures, no provisions have
been established in respect of the claims discussed below.
As discussed in the Disclosures, the majority of claims involve highly complex issues. Often these issues are
subject to substantial uncertainties and, therefore, the probability of a loss, if any, being sustained and/or an
estimate of the amount of any loss is difficult to ascertain.
Unless specifically identified below that a provision has been taken, AstraZeneca considers each of the claims
to represent a contingent liability and discloses information with respect to the nature and facts of the cases in
accordance with IAS 37.
There is one matter concerning legal proceedings in the Disclosures, which is considered probable that an
outflow will be required, but for which we are unable to make an estimate of the possible loss or range of possible
losses at this stage.
In cases that have been settled or adjudicated, or where quantifiable fines and penalties have been assessed
and which are not subject to appeal, or where a loss is probable and we are able to make a reasonable estimate
of the loss, AstraZeneca records the loss absorbed or makes a provision for its best estimate of the expected
loss. The position could change over time and the estimates that the Company made, and upon which the
Company have relied in calculating these provisions are inherently imprecise. There can, therefore, be no
assurance that any losses that result from the outcome of any legal proceedings will not exceed the amount of
the provisions that have been booked in the accounts. The major factors causing this uncertainty are described
more fully in the Disclosures and herein.
AstraZeneca has full confidence in, and will vigorously defend and enforce, its IP.
Matters disclosed in respect of the second quarter of 2022 and to 29 July 2022
Patent litigation
Enhertu
US patent proceedings
As previously disclosed, in October 2020, Seagen Inc. (Seagen) filed a complaint against Daiichi Sankyo
Company, Limited (Daiichi Sankyo) in the US District Court for the Eastern District of Texas (the Court) alleging
that Enhertu infringes US Patent No. 10,808,039 (the ‘039 patent). AstraZeneca co-commercialises Enhertu
with Daiichi Sankyo, Inc. in the US. The trial took place in April 2022. The jury found that the ‘039 patent was
infringed and awarded Seagen $41.82m in past damages. In July 2022, the Court decided not to enhance
damages based on the jury’s finding of willfulness and entered judgment for Seagen. The parties await
consideration of post-trial motions.
47
Total Revenue Financial Performance Sustainability Research and Development Interim Financial Statements
As previously disclosed, in December 2020 and January 2021, AstraZeneca and Daiichi Sankyo filed post-grant
review (PGR) petitions with the US Patent and Trademark Office (USPTO) alleging, inter alia, that the ‘039
patent is invalid for lack of written description and enablement. The USPTO initially declined to institute the
PGRs, but in April 2022, the USPTO granted the rehearing requests, instituting both PGR petitions. Seagen
subsequently disclaimed all patent claims at issue in one of the PGR proceedings. In July 2022, the USPTO
reversed its institution decision and declined to institute AstraZeneca and Daiichi Sankyo’s other PGR petition.
Faslodex
Patent Proceedings outside the US
As previously disclosed, in Japan, Sandoz K.K. and Sun Pharma Japan Ltd are seeking to invalidate the
Faslodex formulation patent at the Japan Patent Office (JPO) and AstraZeneca is defending the challenged
patent. The JPO held the hearing in the matter in May 2022. A decision is awaited.
Lokelma
US patent proceedings
In July 2022, AstraZeneca received Paragraph IV notices from multiple ANDA filers relating to patents listed in
the FDA Orange Book with reference to Lokelma. AstraZeneca is reviewing the notices in preparation for
litigation.
Symbicort
US patent proceedings
As previously disclosed, AstraZeneca is involved in ongoing ANDA patent litigation with Mylan Pharmaceuticals
Inc. (Mylan) and Kindeva Drug Delivery L.P. (Kindeva) brought in the US District Court for the Northern District
of West Virginia (the District Court). A trial in the matter was held in May 2022 and closing arguments were held
in June 2022. A decision is awaited.
As previously disclosed, in April 2022, AstraZeneca filed a separate ANDA action against Mylan and Kindeva
in the District Court asserting infringement of a patent covering Symbicort. In June 2022, Mylan and Kindeva
responded and claim noninfringement of the asserted patent and that the asserted patent is invalid. A trial in
the matter is scheduled for November 2022.
Tagrisso
US patent proceedings
As previously disclosed, in September 2021, Puma Biotechnology, Inc. and Wyeth LLC filed a patent
infringement lawsuit in the US District Court for the District of Delaware against AstraZeneca relating to
Tagrisso. A claim construction hearing has been scheduled for January 2023 and a trial has been scheduled
for May 2024.
Patent proceedings outside the US
As previously disclosed, in Russia, in October 2021, AstraZeneca filed a lawsuit in the Arbitration Court of the
Moscow Region against Axelpharm, LLC to prevent it from obtaining authorisation to market a generic version
of Tagrisso prior to the expiration of AstraZeneca’s patents covering Tagrisso. The lawsuit also names the
Ministry of Health of the Russian Federation as a third party. In March 2022, the court dismissed the lawsuit. In
June 2022, the dismissal was affirmed on appeal, and AstraZeneca is considering its options.
Commercial litigation
Array BioPharma
As previously disclosed, in the US, in December 2017, AstraZeneca was served with a complaint filed in New
York State court by Array BioPharma, Inc. (Array) alleging breaches of contractual obligations relating to a 2003
collaboration agreement between AstraZeneca and Array. In May 2022, the parties resolved this dispute. This
matter is now concluded.
Portola Shareholder Litigation
48
Total Revenue Financial Performance Sustainability Research and Development Interim Financial Statements
As previously disclosed, in the US, in connection with Alexion’s July 2020 acquisition of Portola
Pharmaceuticals, Inc (Portola), Alexion assumed litigation to which Portola is a party. In January 2020, putative
securities class action lawsuits were filed in the US District Court for the Northern District of California against
Portola and certain officers and directors, on behalf of purchasers of Portola publicly traded securities during
the period 8 January 2019 through 26 February 2020.The complaints allege that defendants made materially
false and/or misleading statements or omissions with regard to Andexxa. In June 2022, the parties reached a
settlement in principle of this matter, which is subject to court approval. A provision has been recognised in the
quarter.
Seroquel XR (Antitrust Litigation)
As previously disclosed, in the US, in 2019, AstraZeneca was named in several related complaints which are
currently pending in the US District Court for the District of Delaware (the Court), including several putative class
action lawsuits that were purportedly brought on behalf of classes of direct purchasers or end payors of Seroquel
XR. The complaints allege that AstraZeneca and two different generic drug manufacturers violated antitrust
laws when settling patent litigation related to Seroquel XR. In July 2022, in response to AstraZeneca’s motions,
the Court dismissed all plaintiffs’ claims to the extent they were based on the settlement with one of the generic
manufacturers but denied the motions with respect to certain claims relating to the second generic manufacturer
and allowed such claims to proceed.
Matters disclosed in respect of the first quarter of 2022 and to 29 April 2022
Patent litigation
Enhertu
US patent proceedings
As previously disclosed, in October 2020, Seagen Inc. (Seagen) filed a complaint against Daiichi Sankyo
Company, Limited (Daiichi Sankyo) in the US District Court for the Eastern District of Texas alleging that Enhertu
infringes US Patent No. 10,808,039 (the ‘039 patent). AstraZeneca co-commercialises Enhertu with Daiichi
Sankyo, Inc. in the US. The trial took place in April 2022. The jury found that the ‘039 patent was infringed and
awarded Seagen $41.82m in past damages. The parties await the schedules for a bench trial on equitable
issues and for consideration of post-trial motions.
As previously disclosed, in December 2020 and January 2021, AstraZeneca and Daiichi Sankyo filed post-grant
review petitions with the US Patent and Trademark Office (USPTO) alleging, inter alia, that the ‘039 patent is
invalid for lack of written description and enablement. The USPTO initially declined to institute the post-grant
reviews, but in April 2022, the USPTO granted the rehearing requests, instituting both post-grant review
petitions. An oral hearing is scheduled for January 2023 and a decision is expected by April 2023.
Imfinzi
US patent proceedings
In March 2022, Bristol-Myers Squibb Co. and E.R. Squibb & Sons, LLC filed a lawsuit in US District Court for
the District of Delaware against AstraZeneca alleging that AstraZeneca’s marketing of Imfinzi infringes several
of their patents. No trial date has been scheduled.
Patent proceedings outside the US
In February 2022, Ono Pharmaceuticals filed a lawsuit in Tokyo District Court, Civil Division against
AstraZeneca alleging that AstraZeneca’s marketing of Imfinzi in Japan infringes several of their patents. No trial
date has been scheduled.
Symbicort
US patent proceedings
As previously disclosed, AstraZeneca is involved in ongoing ANDA patent litigation with Mylan Pharmaceuticals
Inc. (Mylan) and Kindeva Drug Delivery L.P. (Kindeva) brought in the US District Court for the Northern District
of West Virginia (the District Court). In March 2022, the US Court of Appeals for the Federal Circuit (the Federal
Circuit) denied AstraZeneca’s Combined Petition for Panel Rehearing and Rehearing En Banc of the Federal
Circuit’s December 2021 decision and the case was remanded back to the District Court for further proceedings.
In April 2022, the District Court entered a Stipulation and Order dismissing patent infringement claims related
49
Total Revenue Financial Performance Sustainability Research and Development Interim Financial Statements
to various asserted patents and otherwise narrowing the issues for trial. A trial in the matter is scheduled to
commence in May 2022.
In April 2022, AstraZeneca filed another ANDA action against Mylan and Kindeva in the District Court asserting
patent infringement.
Tagrisso
US patent proceedings
In February 2020, in response to Paragraph IV notices from multiple ANDA filers, AstraZeneca filed patent
infringement lawsuits in the US District Court for the District of Delaware. In its complaint, AstraZeneca alleged
that a generic version of Tagrisso, if approved and marketed, would infringe a US Orange Book-listed Tagrisso
patent. In the fourth quarter of 2021, AstraZeneca entered into settlement agreements with Zydus
Pharmaceuticals (USA) Inc., Cadila Healthcare Limited, MSN Laboratories Pvt. Ltd., and MSN Pharmaceuticals
Inc. In April 2022, AstraZeneca entered into a settlement agreement with Alembic Pharmaceuticals Limited.
These settlements resolve all US patent litigation between the parties relating to Tagrisso.
Patent proceedings outside the US
In Russia, in October 2021, AstraZeneca filed a lawsuit in the Arbitration Court of the Moscow Region against
Axelpharm, LLC to prevent it from obtaining authorisation to market a generic version of Tagrisso prior to the
expiration of AstraZeneca’s patents covering Tagrisso. The lawsuit also names the Ministry of Health of the
Russian Federation as a third party. In March 2022, the court dismissed the lawsuit, and AstraZeneca has filed
an appeal.
Ultomiris
As previously disclosed, Chugai Pharmaceutical Co., Ltd. (Chugai) filed lawsuits against Alexion in the Delaware
District Court as well as in Tokyo District Court, alleging that Ultomiris infringed US and Japanese patents held
by Chugai.
In March 2022, Alexion entered into a settlement agreement with Chugai that resolves all patent disputes
between the two companies related to Ultomiris.
In accordance with the settlement agreement, Alexion and Chugai have taken steps to withdraw patent
infringement proceedings filed with US District Court for the District of Delaware and Tokyo District Court. Under
the terms of the agreement, Alexion made a single payment of $775m in the second quarter of 2022, for which
a related charge was recognised through the non-core P&L in the first quarter of 2022. No further amounts are
payable by either party.
Product liability litigation
Onglyza and Kombiglyze
In the US, AstraZeneca is defending various lawsuits alleging heart failure, cardiac injuries, and/or death from
treatment with Onglyza or Kombiglyze. In February 2018, the Judicial Panel on Multidistrict Litigation ordered
the transfer of various pending federal actions to the US District Court for the Eastern District of Kentucky (the
District Court) for consolidated pre-trial proceedings with the federal actions pending in the District Court. In the
previously disclosed California State Court coordinated proceeding, AstraZeneca’s motion for summary
judgment was granted in March 2022. A motion for summary judgment is pending in the District Court.
Commercial litigation
Pay Equity Litigation (US)
AstraZeneca is defending a putative class and collective action matter in the US District Court for the Northern
District of Illinois brought by three named plaintiffs, who are former AstraZeneca pharmaceutical sales
representatives. The case involves claims under the federal and Illinois Equal Pay Acts, with the plaintiffs
alleging they were paid less than male employees who performed substantially similar and/or equal work. The
plaintiffs seek various damages on behalf of themselves and the putative class and/or collective, including
without limitation backpay, liquidated damages, compensatory and punitive damages, attorneys’ fees, and
interest.
The Court has not set a trial date and no class or collective certification has been sought or granted as of this
time.
50
Total Revenue Financial Performance Sustainability Research and Development Interim Financial Statements
Government investigations/proceedings
COVID-19 Vaccine Supply and Manufacturing Inquiries
As previously disclosed, in June 2021, Argentina’s Federal Criminal Prosecutor’s Office (the Prosecutor)
contacted AstraZeneca Argentina seeking documents and electronic records in connection with a local criminal
investigation relating to the public procurement and supply of Vaxzevria in that country. In October 2021, the
Prosecutor filed a submission with the presiding court requesting dismissal of the criminal investigation, and
that request was granted by the court in February 2022. This matter is now closed.
In February 2022, a Brazilian Public Prosecutor filed a lawsuit against several defendants including the Brazilian
Federal Government, AstraZeneca, and other COVID-19 vaccine manufacturers. In April 2022, a Brazilian Court
issued an order dismissing the lawsuit.
US 340B Litigations and Proceedings
As previously disclosed, AstraZeneca is involved in several matters relating to its contract pharmacy recognition
policy under the 340B Drug Pricing Program in the US. AstraZeneca has sought to intervene in three lawsuits
against several US government agencies and their officials relating to the appropriate interpretation of the
governing statute for the 340B Drug Pricing Program. Two of the three cases are currently stayed pending
further proceedings and the third case has been dismissed. Administrative Dispute Resolution proceedings
have also been initiated against AstraZeneca before the US Health Resources and Services Administration.
As previously disclosed, in January 2021, AstraZeneca filed a separate lawsuit in federal court in Delaware
alleging that an Advisory Opinion issued by the Department of Health and Human Services violates the
Administrative Procedure Act. In June 2021, the Court found in favour of AstraZeneca, invalidating the Advisory
Opinion. Prior to the Court’s ruling, however, in May 2021, the US government issued new and separate letters
to AstraZeneca (and other companies) asserting that our contract pharmacy policy violates the 340B statute.
AstraZeneca amended the complaint to include allegations challenging the letter sent in May, and in February
2022, the Court ruled in favour of AstraZeneca invalidating those letters sent by the US Government. The US
government has appealed the decision.
51
Table 26: H1 2022 – Product Sales year-on-year analysis90
The CER information in respect of H1 2022 included in the Interim financial statements has not been reviewed by PricewaterhouseCoopers LLP.
World Emerging Markets US Europe Established RoW
$m Act % chg CER % chg $m Act % chg CER % chg $m % Change $m Act % chg CER % chg $m Act % chg CER % chg
Oncology 7,089 14 18 1,792 10 12 2,979 22 1,341 13 24 977 1 12
Tagrisso 2,704 10 14 805 16 17 951 11 509 9 19 439 1 12
Imfinzi 1,294 12 16 134 1 2 689 15 267 18 29 204 1 12
Lynparza 1,291 14 18 241 30 32 582 11 329 9 20 139 15 27
Calquence 903 84 87 16 n/m n/m 735 65 122 n/m n/m 30 n/m n/m
Enhertu 29 n/m n/m 19 n/m n/m – – 8 n/m n/m 2 n/m n/m
Orpathys 23 n/m n/m 23 n/m n/m – – – – – – – –
Zoladex 477 2 7 332 12 14 7 (14) 68 (8) – 70 (21) (11)
Faslodex 178 (21) (16) 81 1 5 10 (36) 32 (54) (50) 55 (8) 3
Iressa 63 (41) (39) 52 (41) (40) 4 (24) 1 (55) (44) 6 (44) (36)
Arimidex 61 (17) (13) 47 (16) (15) – 1 1 (69) (69) 13 (14) (1)
Casodex 42 (49) (47) 27 (58) (58) – n/m 1 49 21 14 (19) (11)
Others 24 (4) 3 15 4 9 1 n/m 3 6 16 5 (32) (24)
BioPharmaceuticals: CVRM* 4,559 14 18 2,099 9 12 1,151 10 945 28 40 364 21 33
Farxiga 2,103 55 63 814 46 50 468 55 627 69 85 194 55 70
Brilinta 675 (10) (7) 146 (19) (15) 351 (2) 150 (16) (8) 28 (12) (8)
Lokelma 129 79 87 5 n/m n/m 78 58 13 n/m n/m 33 n/m n/m
Roxadustat 91 1 1 91 1 1 – – – – – – – –
Andexxa* 70 9 12 – – – 42 (23) 18 90 n/m 10 n/m n/m
Crestor 547 2 6 414 11 15 35 (15) 21 (36) (30) 77 (18) (10)
Seloken/Toprol-XL 467 (9) (7) 456 (9) (7) – n/m 6 5 2 5 (10) 1
Bydureon 141 (29) (28) 2 1 3 119 (27) 20 (31) (25) – (93) (93)
Onglyza 139 (31) (28) 66 (39) (36) 40 (9) 21 (32) (26) 12 (29) (28)
Others 197 (9) (7) 105 (2) – 18 (35) 69 (6) (4) 5 (27) (20)
BioPharmaceuticals: R&I 2,891 (2) – 731 (17) (16) 1,300 13 551 (11) (3) 309 (1) 6
Symbicort 1,288 (6) (3) 306 – 3 481 (9) 312 (9) (1) 189 (1) 4
Fasenra 662 14 18 17 n/m n/m 419 18 153 12 23 73 (8) 1
Pulmicort 334 (33) (32) 236 (42) (41) 37 5 35 3 13 26 13 20
Breztri 179 n/m n/m 43 61 61 106 n/m 14 n/m n/m 16 46 65
Saphnelo 36 n/m n/m – – – 34 n/m 1 n/m n/m 1 n/m n/m
Daliresp 109 (5) (4) 1 (32) (30) 102 (2) 5 (37) (31) 1 16 18
Bevespi 30 13 16 3 49 47 22 9 5 21 32 – (26) 43
Others 253 (13) (12) 125 (8) (8) 99 65 26 (71) (68) 3 (50) (48)
BioPharmaceuticals: V&I 2,734 n/m n/m 861 89 92 638 n/m 511 (17) (10) 724 n/m n/m
Vaxzevria 1,540 36 41 660 45 45 80 n/m 262 (54) (50) 538 n/m n/m
Evusheld 914 n/m n/m 93 n/m n/m 556 n/m 143 n/m n/m 122 n/m n/m
Synagis 280 n/m n/m 108 n/m n/m 2 (55) 106 n/m n/m 64 n/m n/m
FluMist – n/m n/m – n/m n/m – – – n/m n/m – – –
Rare Disease* 3,495 5 10 206 (24) (8) 2,090 7 733 1 12 466 17 30
Soliris* 2,017 (5) 1 134 (45) (29) 1,165 2 437 (17) (8) 281 34 46
Ultomiris* 853 22 28 30 n/m n/m 456 10 225 65 81 142 (3) 11
Strensiq* 450 11 13 18 24 16 353 12 40 – 9 39 4 18
Koselugo 101 n/m n/m 15 n/m n/m 78 65 8 n/m n/m – – –
Kanuma* 74 9 14 9 4 12 38 11 23 7 18 4 16 20
Other medicines 842 (11) (6) 395 (26) (24) 75 (21) 67 (32) (28) 305 38 54
Nexium 674 (9) (2) 289 (31) (28) 63 (5) 26 (26) (19) 296 36 52
Others 168 (21) (20) 106 (9) (8) 12 (59) 41 (36) (34) 9 n/m n/m
Total Product Sales 21,610 41 47 6,084 12 15 8,233 74 4,148 28 40 3,145 65 81
90 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. Due to rounding, the sum of a number of dollar values and
percentages may not agree to totals. * FY 2022 Q2 growth rates on medicines acquired with Alexion have been calculated on a pro forma basis comparing to the corresponding period in the prior
year, pre-acquisition as previously published by Alexion. The growth rates shown for Rare Disease and CVRM disease area totals include these pro forma adjustments.
52
Table 27: Q2 2022 – Product Sales year-on-year analysis (Unreviewed)91
The Q2 2022 information in respect of the three months ended 30 June 2022 included in the Interim financial statements has not been reviewed by PricewaterhouseCoopers LLP.
World Emerging Markets US Europe Established RoW
$m Act % chg CER % chg $m Act % chg CER % chg $m % Change $m Act % chg CER % chg $m Act % chg CER % chg
Oncology 3,701 14 18 897 4 6 1,605 26 691 14 26 508 (1) 12
Tagrisso 1,400 7 12 400 2 4 513 17 256 5 17 231 (1) 12
Imfinzi 695 15 20 75 – 1 374 22 142 21 34 104 (2) 11
Lynparza 673 15 20 120 21 23 312 16 169 11 23 72 8 23
Calquence 489 74 77 8 80 77 396 59 67 n/m n/m 18 n/m n/m
Enhertu 18 n/m n/m 12 n/m n/m – – 4 n/m n/m 2 n/m n/m
Orpathys 11 n/m n/m 11 n/m n/m – – – – – – – –
Zoladex 236 (3) 2 165 3 7 3 (7) 34 (7) 3 34 (23) (14)
Faslodex 86 (18) (11) 37 (1) 3 5 (29) 16 (48) (42) 28 (8) 5
Iressa 32 (32) (29) 26 (28) (26) 2 (32) – (63) (43) 4 (48) (39)
Arimidex 28 (1) 5 22 8 11 – (45) – (93) (93) 6 (19) (4)
Casodex 21 (50) (48) 14 (57) (57) – (99) 1 n/m n/m 6 (29) (19)
Others 12 (8) 1 7 5 11 – – 2 (14) (4) 3 (35) (25)
BioPharmaceuticals: CVRM* 2,352 14 19 1,074 10 14 629 14 463 26 39 186 16 30
Farxiga 1,103 51 59 423 42 47 275 61 309 56 74 96 45 63
Brilinta 350 (7) (4) 78 4 8 185 (5) 73 (19) (10) 14 (17) (14)
Lokelma 66 68 79 2 89 n/m 39 55 7 n/m n/m 18 78 n/m
Roxadustat 50 (2) (1) 50 (2) (1) – – – – – – – –
Andexxa* 37 5 11 – – – 18 (37) 9 49 61 10 n/m n/m
Crestor 280 6 11 217 19 24 16 (14) 10 (14) (4) 37 (30) (22)
Seloken/Toprol-XL 223 (16) (13) 218 (16) (13) – – 3 (3) (4) 2 (13) 1
Bydureon 73 (23) (22) 1 (20) (18) 62 (20) 10 (34) (26) – (95) (95)
Onglyza 71 (28) (25) 32 (36) (32) 22 (15) 10 (33) (26) 7 (8) (7)
Others 99 (1) 1 53 (8) (7) 12 (6) 32 19 22 2 (28) (19)
BioPharmaceuticals: R&I 1,381 (3) 1 294 (14) (12) 654 10 274 (14) (4) 159 (2) 6
Symbicort 614 (10) (6) 139 (1) 2 222 (16) 155 (12) (3) 98 (1) 5
Fasenra 354 11 15 10 94 89 230 15 78 6 18 36 (11) –
Pulmicort 116 (30) (28) 72 (40) (39) 15 (16) 17 (4) 8 12 3 12
Breztri 93 66 72 21 20 21 53 71 9 n/m n/m 10 47 69
Saphnelo 24 n/m n/m – – – 23 n/m – – – 1 n/m n/m
Daliresp 58 7 8 1 (37) (34) 54 11 3 (27) (19) – 34 38
Bevespi 15 12 17 1 46 73 11 8 3 25 39 – (59) 49
Others 107 (18) (17) 50 (14) (14) 46 90 9 (79) (77) 2 (47) (45)
BioPharmaceuticals: V&I 977 10 15 231 (44) (44) 252 n/m 225 (39) (32) 269 n/m n/m
Vaxzevria 451 (48) (44) 185 (55) (55) – – 128 (63) (59) 138 36 50
Evusheld 445 n/m n/m 4 n/m n/m 250 n/m 77 n/m n/m 114 n/m n/m
Synagis 80 n/m n/m 42 n/m n/m 2 (32) 19 (9) (6) 17 n/m n/m
FluMist 1 n/m n/m – – – – – 1 n/m n/m – n/m n/m
Rare Disease* 1,801 6 12 91 (35) (19) 1,070 8 373 2 15 267 33 50
Soliris* 1,027 (5) 2 63 (48) (30) 574 (2) 216 (19) (8) 174 63 81
Ultomiris* 434 23 31 6 21 25 236 14 120 76 98 72 (3) 15
Strensiq* 242 16 18 9 1 (13) 193 21 21 – 12 19 2 17
Koselugo 62 n/m n/m 10 n/m n/m 47 83 5 n/m n/m – – –
Kanuma* 36 9 13 3 (36) (39) 20 15 11 15 30 2 22 24
Other medicines 418 (3) 6 191 (20) (16) 36 (17) 31 (33) (29) 160 60 84
Nexium 343 2 12 145 (22) (17) 30 (13) 12 (35) (28) 156 59 82
Others 75 (19) (17) 46 (14) (13) 6 (32) 19 (32) (30) 4 n/m n/m
Total Product Sales 10,630 32 38 2,778 (2) 1 4,246 72 2,057 21 34 1,549 49 67
91 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. Due to rounding, the sum of a number of dollar values and
percentages may not agree to totals. * FY 2022 Q2 growth rates on medicines acquired with Alexion have been calculated on a pro forma basis comparing to the corresponding period in the prior
year, pre-acquisition as previously published by Alexion. The growth rates shown for Rare Disease and CVRM disease area totals include these pro forma adjustments.
53
Table 28: Collaboration Revenue
H1 2022 H1 2021
$m $m
Lynparza: regulatory milestones 175 –
Enhertu: share of gross profits 173 83
Vaxzevria: royalties 60 33
Tezspire: share of gross profits 16 –
Tralokinumab: sales milestones 70 –
Other royalty income 37 36
Other Collaboration Revenue 20 86
Total 551 238
Table 29: Other Operating Income and Expense
H1 2022 H1 2021
$m $m
Brazikumab licence termination funding 69 51
Divestment of rights to Plendil 61 –
Divestment of Viela Bio, Inc. shareholding – 776
Crestor (Europe ex-UK and Spain) – 309
Other 89 172
Total 219 1,308
Other shareholder information
Financial calendar
Announcement of year to date and third quarter results 10 November 2022
Announcement of full year and fourth quarter results 9 February 2023
Dividends are normally paid as follows:
First interim: Announced with the half year results and paid in September
Second interim: Announced with full year results and paid in March
The record date for the first interim dividend for 2022, payable on 12 September 2022, will be 12 August 2022.
The ex-dividend date will be 11 August 2022.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
54
Addresses for correspondence
Registered office Registrar and
transfer office
Swedish Central
Securities Depository
US depositary
Deutsche Bank Trust
Company Americas
1 Francis Crick Avenue
Cambridge Biomedical
Campus
Cambridge
CB2 0AA
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex
BN99 6DA
Euroclear Sweden AB PO
Box 191
SE-101 23 Stockholm
American Stock Transfer
6201 15th Avenue
Brooklyn
NY 11219
United Kingdom United Kingdom Sweden United States
+44 (0) 20 3749 5000 0800 389 1580 +46 (0) 8 402 9000 +1 (888) 697 8018
+44 (0) 121 415 7033 +1 (718) 921 8137
[email protected]
Trademarks
Trademarks of the AstraZeneca group of companies appear throughout this document in italics. Medical
publications also appear throughout the document in italics. AstraZeneca, the AstraZeneca logotype and the
AstraZeneca symbol are all trademarks of the AstraZeneca group of companies. Trademarks of companies
other than AstraZeneca that appear in this document include Arimidex and Casodex, owned by AstraZeneca or
Juvisé (depending on geography); Enhertu, a trademark of Daiichi Sankyo; Seloken, owned by AstraZeneca or
Taiyo Pharma Co., Ltd (depending on geography); Synagis, owned by AstraZeneca or AbbVie Inc. (depending
on geography); and Tezspire, a trademark of Amgen, Inc.
Information on or accessible through AstraZeneca’s websites, including astrazeneca.com, does not form part
of and is not incorporated into this announcement.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and
BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in
Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions
of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
55
Cautionary statements regarding forward-looking statements
In order, among other things, to utilise the ‘safe harbour’ provisions of the US Private Securities Litigation Reform
Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement:
This document contains certain forward-looking statements with respect to the operations, performance and
financial condition of the Group, including, among other things, statements about expected revenues, margins,
earnings per share or other financial or other measures. Although the Group believes its expectations are based
on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and
uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially
different from those predicted. The forward-looking statements reflect knowledge and information available at
the date of preparation of this document and the Group undertakes no obligation to update these forward-looking
statements. The Group identifies the forward-looking statements by using the words ‘anticipates’, ‘believes’,
‘expects’, ‘intends’ and similar expressions in such statements. Important factors that could cause actual results
to differ materially from those contained in forward-looking statements, certain of which are beyond the Group’s
control, include, among other things:
‒ the risk of failure or delay in delivery of pipeline or launch of new medicines
‒ the risk of failure to meet regulatory or ethical requirements for medicine development or approval
‒ the risk of failures or delays in the quality or execution of the Group’s commercial strategies
‒ the risk of pricing, affordability, access and competitive pressures
‒ the risk of failure to maintain supply of compliant, quality medicines
‒ the risk of illegal trade in the Group’s medicines
‒ the impact of reliance on third-party goods and services
‒ the risk of failure in information technology or cybersecurity
‒ the risk of failure of critical processes
‒ the risk of failure to collect and manage data in line with legal and regulatory requirements and strategic
objectives
‒ the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce
‒ the risk of failure to meet regulatory or ethical expectations on environmental impact, including climate
change
‒ the risk of the safety and efficacy of marketed medicines being questioned
‒ the risk of adverse outcome of litigation and/or governmental investigations
‒ intellectual property-related risks to our products
‒ the risk of failure to achieve strategic plans or meet targets or expectations
‒ the risk of failure in financial control or the occurrence of fraud
‒ the risk of unexpected deterioration in the Group’s financial position
‒ the impact that global and/or geopolitical events such as the COVID-19 pandemic and the Russia-Ukraine
war, may have or continue to have on these risks, on the Group’s ability to continue to mitigate these risks,
and on the Group’s operations, financial results or financial condition
Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.
– End of document –